I8F-MC-GPGF Clinica l Protocol  
A Phase 2, Double- Blind, Placebo- Controlled, 3-Month Trial of LY3298176 versus Placebo in 
Patients with T ype  2 D iabetes Mellitus . 
[STUDY_ID_REMOVED] 
Approval Date: 
02-A ug-2017 
I8F-MC-GPGF Cli nical Protocol Page 1
LY3298176Protocol I8F-MC-GPGF
A Phase 2, Double -Blind, Placebo -Controlled, 3-MonthTrial 
of LY3298176 versus Placebo in Patients with 
Type 2 Diabetes Mellitus
Confidential Information
The information contained in this document is confidential and is intended for the use of 
clinical investigators.  It is the property of Eli Lilly and Company or its subsidiaries and 
should not be copi[INVESTIGATOR_506228]3298176 , unless such persons are bound by a confidentiality agreement with Eli Lilly 
and Company or its subsidiaries.  
Note to Regulatory Authorities :  This document may contain protected personal data 
and/or commercially confiden tial information exempt from public disclosure. Eli Lilly and 
Company requests consultation regarding release/redaction prior to any public release. In 
the [LOCATION_002], this document is subject to Freedom of Information Act (FOIA) 
Exemption 4 and may n ot be reproduced or otherwise disseminated without the written 
approval of Eli Lilly and Company or its subsidiaries.
LY3298176
This is a randomized, d ouble -blind, parallel -arm, placebo -controlled, Phase 2 ,multicenter 
study in patients with type 2 diabe tes mellitus .
Eli Lilly and Company
Indianapolis, Indiana [LOCATION_003] [ZIP_CODE]
Protocol Electronically Signed and Approved by L illyon date provided below.
Approval Date: 02-Aug-[ADDRESS_1152387] ivities....................................................................................................... 11
3. Introduction ...................................................................................................................... 16
3.1. Study  Rati onale ............................................................................................................ 16
3.2. Background .................................................................................................................. 16
3.3. Benefit /Risk Assessment .............................................................................................. [ADDRESS_1152388] ions/Requirements ...................................................................... 33
7.3. Blinding ....................................................................................................................... 34
7.4. Dosage Modification .................................................................................................... 35
7.5. Preparati on/Handling/Storage/Accountabilit y............................................................... 35
7.6. Treatment Compliance .................................................................................................35
7.7. Concomitant Therapy ................................................................................................... 36
7.8. Treatment after the End of the Study ............................................................................ 37
7.8.1. Speci al Treatm ent Consi derat ions (Rescue Therapy) ............................................ [ADDRESS_1152389] to Follow -Up........................................................................................................ 40
9. Study  Assessments and Procedures ................................................................................... 41
9.1. Efficacy Assessments ................................................................................................... 41
9.1.1. Primary Efficacy  Assessments ............................................................................. 41
9.1.2. Secondary  Efficacy  Assessments .......................................................................... 41
[IP_ADDRESS]. Exploratory  Efficacy  Assessments .................................................................. 41
9.1.3. Appropriateness of Assessments .......................................................................... 42
9.2. Adverse Events ............................................................................................................ 42
9.2.1. Serious Adverse Events ........................................................................................ 43
[IP_ADDRESS]. Suspected Unexpected Serious Adverse React ions.......................................... 43
[IP_ADDRESS]. Adverse Events of Special Interest .................................................................. 44
[IP_ADDRESS].1. Nausea, Vomit ing, and Diarrhea ............................................................... 44
[IP_ADDRESS].2. Inject ion Site Reacti ons ............................................................................ 44
[IP_ADDRESS].3. Hypersensi tivity Reacti ons........................................................................ 44
[IP_ADDRESS].4. Hypoglycemia ........................................................................................... 45
[IP_ADDRESS].5. Acute Pancreat itis..................................................................................... 45
[IP_ADDRESS].6. Major Adverse Cardio vascular Events ...................................................... 46
[IP_ADDRESS].7. Thyroid C-Cell Hyperpl asia and C -Cell Neoplasms .................................. [ADDRESS_1152390] ical Considerat ions........................................................................ 52
10.3.2. Treatment Group Comparabilit y........................................................................... 53
[IP_ADDRESS]. Patient Disposi tion.......................................................................................... 53
[IP_ADDRESS]. Patient Characteri stics.................................................................................... 53
[IP_ADDRESS]. Concomitant Therapy ..................................................................................... 53
[IP_ADDRESS]. Treatment Compliance .................................................................................... 53
10.3.3. Efficacy Analyses ................................................................................................ 54
[IP_ADDRESS]. Primary Analyses ........................................................................................... 54
[IP_ADDRESS]. Secondary  Analyses ........................................................................................ 54
[IP_ADDRESS].1. Analyses on Secondary  Efficacy Endpoints ............................................... 54
[IP_ADDRESS]. Exploratory  Analyses ..................................................................................... 55
10.3.4. Safety Analyses .................................................................................................... 55
[IP_ADDRESS]. Clinical Evaluation of Safet y.......................................................................... 55
[IP_ADDRESS]. Adverse Events ............................................................................................... 56
[IP_ADDRESS]. Vital Signs...................................................................................................... 56
[IP_ADDRESS]. Laboratory  Measures ...................................................................................... 56
[IP_ADDRESS]. Evaluat ion of Immunogenicit y........................................................................ 56
[IP_ADDRESS]. Adverse Events of Special Interest .................................................................. 57
[IP_ADDRESS]. Hypoglycemic Epi[INVESTIGATOR_1841] ................................................................................. 57
10.3.5. Pharmacokinet ic/Pharmacodynamic Analyses ...................................................... 57
10.3.6. Other Analyses ..................................................................................................... 58
10.3.6 .1. Subgroup Analyses ......................................................................................... 58
[IP_ADDRESS]. Interim Analyses ............................................................................................. [ADDRESS_1152391] ives and Endpo ints............................................................................... 18
Table GPGF.3. Study  Treatm ents and Dose Titration ............................................................. 32
Table GPGF.4. Dose –Response A ssumpt ion Used in Sample Size Determinat ion.................. [ADDRESS_1152392] of Appendices
Appendix Page
Abbreviat ions and Definit ions........................................................................ 62 Appendix 1.
Clinical Laboratory  Tests ............................................................................... 66 Appendix 2.
Study  Governance Considerat ions.................................................................. 68 Appendix 3.
Hepati c Moni toring Tests for Treatment- Emergent Abnormalit y.................... 72 Appendix 4.
Criteria for Di agnosing Type 2 Di abetes Mellitus (American Dia betes Appendix 5.
Associ ation 2017) .......................................................................................... 73
Contraceptive Methods .................................................................................. 74 Appendix 6.
World Heal th Organizat ion Standardized Protocols for the Appendix 7.
Measurement of Height and Weight ............................................................... 76
I8F-MC-GPGF Clinical Protocol Page 8 
LY3298176 1. Synopsis 
Title of Study:   
A Phase 2, Double-Blind, Placebo-Controlled, 3- Month Trial of LY3298176 versus Placebo in 
Patients with Type 2 Diabetes Mellitus  
Rationale:   Study I8F-MC-GPGF is a 3-month Phase 2 stud y designed to examine the efficacy and 
tolerability of subcutaneously  administered once-weekly (QW) LY3298176 compared with 
placebo in patients with type 2 diabetes mellitus (T2DM) who have inadequate glycemic control 
with diet and exercise alone or with a stable dose of metformin.  This study will use [ADDRESS_1152393] planned dose.  The primary endpoint will be 
the change from baseline in hemoglobin A1c (HbA1c) at the end of study drug treatment.  
Efficacy and tolerability data from this study and from the large Phase 2 study I8F-MC-GPGB 
(GPGB) will be used to set doses and tit ration scheme for the Phase 3 studies. 
Objectives/Endpoints:   
Objectives Endpoints 
Primary 
 To demonstrate that at least 1 LY3298176 titration 
scheme is superior to placebo in hemoglobin A1c (HbA1c) reduction at 3 months in patients with type 2 diabetes mellitus (T2DM) inadequately controlled 
with diet and exercise alon e or treated with a stable 
dose of metformin  
 Change in HbA1c from baseline 
Secondary 
Efficacy 
 To compare each titration scheme to placebo at 
3 months for secondary efficacy parameters    Proportion of patients achieving HbA1c target of <7.0%  
 The change in fasting blood glucose (FBG; central laboratory) from baseline  
 The change in body weight from baseline  
 The change in waist circumference from baseline 
Safety  
 To compare each titration scheme to placebo for selected safety parameters at 3 months   Treatment-emergent adverse events (TEAEs) and serious adverse events (SAEs) 
 Incidence of nausea, vomiting, and diarrhea 
 Discontinuation of study drug due to adverse events (AEs) 
 Incidence and rate of hypoglycemia (severe, total, documented symptomatic, and nocturnal) 
 Incidence of anti-LY3298176 antibodies 
Pharmacokinetics  
 To evaluate the pharmacokinetics (PK) of LY3298176  
 PK trough samples 
  
I8F-MC-GPGF Cli nical Protocol Page 9
LY3298176Summary of Study Design:
LY3298176 is being invest igated for its potential use in the treatment of T2DM.  LY3298176 is 
a long-acting, dual incret in receptor co -agonist that binds to both the glucose -dependent 
insulinotropic polypept ide (GIP) receptor and the glucagon -like peptide -1 (GLP -1) receptor.   
Study  GPG Fis a Phase 2, mult icenter, randomized, double -blind, parallel -arm, placebo -
controlled titration study  designed to evaluate efficacy , tolerabili ty, and safet yof LY3298176 in 
patients wi th T2DM with inadequate glycemic control on diet and exerc ise alone or on a stable 
dose ofmetformin mo notherapy .  
Treatment Arms and Duration:
Study  GBGF includes 4 treatment arms: 3 titration arms of LY3298176 and matching placebo.
Patients will  be randomized in a 1:1:1 :1ratio to 1 of the 3 LY3298176 titration groups or 
placebo .Study  parti cipants will be treated for 3 months after randomizat ion in a double -blind 
manner, followed by a 4 -week safet y evaluat ion. 
Number of Patients:
A total o f approximately  
92 patients (23patients per titration group or placebo )will be 
rando mized ,and approximately 80 are expected to complete the treatment period.  
Statistical Analysis:
Efficacy :  The primary  analysis for the endpoint of the primary  object ive, change from baseline 
in HbA1c at 3months, will be mixed model for repeated m easures (MMRM) analysis. It will be 
perform ed on the m odified intent -to-treat (m ITT) analysis data set.  This model will include
baseline body  mass index ( BMI; <30, 30), m etformin use, treatm ent, vi sit,and treatment -by-
visit as fixed effects, and baseline HbA1c value as a covariate.  
Addit ional covari ates may  be added and will be detailed in the statist ical analysis plan (SAP) .
The m ean weight change from baseline at 3 months will be analyzed using similar MMRM
models as the primary  analysis with treatm ent, vi sit, treatm ent-by-visit, m etformin use, baseline 
HbA1C category  (<8.5%, ≥8.5%) as fixed effects, and baseline body  weight as covariate .  The 
change from baseline o f fasting blood glucose ( FBG) and waist circumference will be analyzed 
using a similar MMRM -based model.  Summaries will include descript ive statistics for 
continuous measures (sample size, mean, standa rd deviat ion [SD], m edian, minimum, and 
maximum) and for categorical measures (sample size, frequency, and percentage).
Safety:  The summary  stati stics for continuous variables will be sample size, mean, SD, median, 
minimum, and maximum.  The summary  stati stics for categori cal vari ables will be sample size, 
frequency , and percentage.  Exposure to each therapy  during the treatm ent peri od of  the study  
will be calculated for each patient and summarized by [CONTACT_1570].  Addit ional analyses, 
such as concentr ation–safet y lab plots, m ay be perform ed if warranted upon review of the data. 
Pharmacokinet ics(PK) /Pharmacodynamics (PD) :  Trough PK samples co llected over the course 
of this study  will be used to assess that LY3298176 exposures in the study  are consistent wi th
known LY3298176 PK. Addit ionally , PK/PD data from  this study  may be used as a validat ion 
dataset to enable evaluat ion of PK/PD models devel oped from  the core Phase 2 study GPGB
I8F-MC-GPGF Cli nical Protocol Page 10
LY3298176data. These analyses may  be conducted using nonlinear mixed -effects m odeling implemented
with the NONMEM software. If posi tive antibody titers to LY3298176 are observed, the 
relationship between ant ibody  titer and LY3298176 PK or any  relevant PD param eters will be 
evaluated.
I8F-MC-GPGF Cli nical Protocol Page 11
LY32981762.Schedule of A ctivities
I8F-MC-GPGF Clinical Protocol Page 12 
LY3298176 Table GPGF.1. Schedule of Activities 
Study Phase Screen Lead-In Randomize Treatment Follow-Up Early Term. 
Visit 1 2 3 4 5 6 7Ta 8 9Ta 10b 801d  ET 
Week of Treatment 2 1 0 1 2 4 4 8 8 12 (15)  
Study Day/(dose number)   0/(1) 7/(2) 14/(3) 28/(5) 31-34 56/(9) 59-62 84 105  
Visit Window (days)  +7 0 0 ±2 ±3  ±3  ±3 ±3  
Administrative              
Informed consent X            
Diabetes medical history/therapy X            
Inclusion/exclusion X X  X          
Preexisting conditions X            
Randomization   X          
IWRS X X X X X X  X  X X X 
BG meter/supplies, if needed  X           
BG meter, instructions  X           
Diet, exercise, BG counseling  X           
Study diary, dispense  X X X X X  X  X   
Review patient diaries for BG 
values, AEs, hypoglycemic or 
hyperglycemic events  X X X X X  X  X X X 
Subcutaneous injection training  X X X X X  X     
Study drug and injection supplies, dispense   X X X X  X     
Health habits (alcohol use, tobacco use current/past) X      
      
Patient returns study drug vials        X  X  X   
Study drug, assess compliance   X X X X  X  X   
Patient Demographics              
Age X            
Gender X            
Race/ethnicity X            
  
I8F-MC-GPGF Clinical Protocol Page 13 
LY3298176 Study Phase Screen Lead-In Randomize Treatment Follow-Up Early Term. 
Visit 1 2 3 4 5 6 7Ta 8 9Ta 10b 801d ET 
Week of Treatment 2 1 0 1 2 4 4 8 8 12 (15)  
Study Day/(dose number)   0/(1) 7/(2) 14/(3) 28/(5) 31-34 56/(9) 59-62 84 105  
Visit Window (days)  +7 0 0 ±2 ±3  ±3  ±3 ±[ADDRESS_1152394] circumference X  X   X  X  X X X 
Vital signs (BP and PR) X X X X X X  X  X X X 
Antidiabetic medication X X X X X X  X  X X X 
Concomitant medication X X X X X X  X  X X X 
Other              
ECGe Xe  X   X  X  X X Xe 
Evaluation of injection site 
reactions   X X X X  X  X X X 
Collect AEs X X X X X X  X  X X X 
Diagnostics (Safety)              
Screening laboratory testsf X            
Pregnancy testg X  Xg          
FSHh X            
Chemistry panel X  X       X X X 
Lipid panel X  X       X X X 
Lipase and amylase X  X   X  X  X X X 
eGFR X            
Hematology X  X       X X X 
Urinalysis X  X       X X X 
 
  
I8F-MC-GPGF Clinical Protocol Page 14 
LY3298176 Study Phase Screen Lead-In Randomize Treatment Follow-Up Early Term. 
Visit 1 2 3 4 5 6 7Ta 8 9Ta 10b 801d ET 
Week of Treatment 2 1 0 1 2 4 4 8 8 12 (15)  
Study Day/(dose number)   0/(1) 7/(2) 14/(3) 28/(5) 31-34 56/(9) 59-62 84 105  
Visit Window (days)  +7 0 0 ±2 ±3  ±3  ±3 ±3  
Diagnostics (Efficacy)              
Calcitonin X         X  X 
HbA1c X  X   X  X  X X X 
Fasting glucose X  X   X  X  X X X 
Total and active GLP-1/GIP   X   X  X  X X  
7-point SMBG   Xi       Xj   
PKk      X  X  X X X 
Immunogenicity   X   X  X  X Xl X 
Nonpharmacogenetic stored 
samples   X       X   
Abbreviations:  AE = adverse event; BG = blood glucose; BP = blood pressure; ECG = electrocardiogram; eGFR = estimated glomerul ar filtration rate; ET = 
Early Termination; FSH = follicle-stimulating hormone; GLP-1 = glucagon-like peptide-1; GIP = glucose-dependent insulinotropic peptide; HbA1c = 
hemoglobin A1c; IWRS = interactive web response system; LH = lu teinizing hormone; PK = pharmacokinetics; PR = pulse rate; SMBG = self-monitoring of 
blood glucose; T = telephone visit; TE = treatment emergent; Term. = termination.   
a Telephone visits occur during the week following a dose escalation and should be done 3 to 6 days after a site visit for dose  escalation and administration.  At 
telephone visits, the sites should call the patient, ask how the patient is, and ask whether the patient would like to come to the site for assistance with the next 
study drug dilution and administration.  Sites should also remind patients to write down any AEs in their diaries at the teleph one visits (as well as at all site 
visits). 
b Visit should occur approximately [ADDRESS_1152395] dose (Dose 12). 
c Additional physical examinations may be performed throughout the study if determined necessary due to patient symptoms. d Visit should occur [ADDRESS_1152396] dose of study drug or 3 weeks after Visit 10. e ECGs should be collected prior to all blood draws and study drug administrations.  Local ECGs will be collected for screening  (Visit 1) and Early 
Termination.  Centralized ECGs, collected in supi[INVESTIGATOR_830350] d in triplicate, should be collected for all other designated vi sits. 
f Screening laboratory tests include serum hepatitis B surface Ag, hepatitis C antibody (Ab), and human immunodeficiency virus (HIV) Ab tests for all patients 
(see Appendix 2). 
g Serum pregnancy test will be performed by  [CONTACT_82408] [ADDRESS_1152397] may be performed at the investigator’s discretion if pregnancy is suspected during the study (local laboratory).   A urine pregnancy test (local) 
should be given to all women of child-bearing potential at Visit [ADDRESS_1152398] 
returned to baseline ADA titer (defined as ADA titer within 2 -fold of baseline ).Patients who have clinical sequelae that are considered potentially related to 
the presence of TE -ADA may also be asked to return for additional follow -up testing.
I8F-MC-GPGF Clinical Protocol Page 16 
LY3298176 3. Introduction  
3.1. Study Rationale 
Study I8F-MC-GPGF (GPGF) is a 3-month Phas e 2 study designed to examine the efficacy, 
safety, and tolerability of subcutaneous ly administered once-weekly (QW) LY3298176 
administered in 3 different titration schemes compared with placebo in  patients with type 2 
diabetes mellitus (T2DM) who have inadequate gly cemic control with diet and exercise alone or 
with a stable dose of metformin monotherapy.  The primary endpoint will be the change in 
hemoglobin A1c (HbA1c) at the end of study drug treatment.  These data  will support selection 
of doses and a titration scheme to attain  the highest dose for Phase 3 trials.   
3.2. Background 
 
 
 
 
  
 
 
 
 
 
 
 
 
 
 
CCI
I8F-MC-GPGF Cli nical Protocol Page 17
LY3298176 
 
 
 
 
 
 
 
 
3.3. Benefit/Risk Assessment
More informat ion about the known and expected benefits, risks ,serious adverse events (SAEs), 
and reasonably ant icipated AEs ofLY3298176 maybe found in the Investigator’s Brochure (IB). 
Inform ation on AEs expected to be related to the investigational product may be found in 
Secti on7(Development Core Safet y Inform ation)of the IB.  Informat ion on SAEs that are 
expected in the study  popul ation independent of drug exposure will be assessed by [CONTACT_365191] , periodically during the course of the study, and may be found in Section 6 (Effects in 
Hum ans) of  the IB.
CCI
I8F-MC-GPGF Cli nical Protocol Page [ADDRESS_1152399] ives and endpo ints ofthe study .
Table GPG F.2. Objectives and Endpoints
Objectives Endpoints
Primary
To demonstrate that at least 1 LY3298176 titration 
scheme is superior to placebo in HbA1c reduction at 
3months in patients with T2DM inadequately 
controlled with diet and exercise alone or treated with 
a stable dose of metforminChange in HbA1c from baseline
Secondary
Efficacy
To compare each titration scheme to placebo at 
3months for secondary efficacy parametersProportio n of patients achieving HbA1c target of 
<7.0% 
The change in FBG (central laboratory) from baseline 
The change in body weight from baseline 
The change in waist circumference from baseline
Safety
To compare each titration scheme to placebo for 
selected safety parameters at 3 monthsTEAEs and SAEs
Incidence of nausea, vomiting, and diarrhea
Discontinuation of study drug due to AEs
Incidence and rate of hypoglycemia (severe, total, 
documented symptomatic, and nocturnal)
Incidence of anti -LY3298176 antibodies
Pharmacokinetics 
To evaluate the PK of LY3298176 PK trough samples
Exploratory
Tocompare each t itration scheme to placebo at 
3months for effect on SMBG profile.SMBG values at baseline and end of treatment.
Abbreviations:  AE = adverse event; FBG = fasting blood glucose; HbA1c = hemoglobin A1c ; PK = 
pharmacokinetics; SAE = serious adverse event; SMBG = self-monito ring of blood glucose ; T2DM= type 2 
diabetes mellitus ; TEAE = treatment -emergent adverse event .  
I8F-MC-GPGF Cli nical Protocol Page [ADDRESS_1152400] of 3 treatm ent peri ods: approximately 1-week l ead-in peri od, followed by 
a 3-monthtreatment period, and a 4 -week safet y follow-up peri od(see Figure GPG F .1).  A
doubl e
-dummy dose administration scheme will be em ployed to ensure patients and investigato rs 
(as well as sponsor study  team  and m onitors) remain blind to the LY3298176 and placebo
treatm ent assi gnments within each titration group.
Placebo
Group 1
2.5mg 2.5mg 5mg 5mg 10mg 10mg 10mg 10mg 15mg 15mg 15mg 15mg
Group 2
2.5mg 2.5mg 2.5mg 2.5mg 7.5mg
7.5mg 7.5mg 7.5mg 15mg 15mg 15mg 15mg
Group 3
4mg 4mg 4mg 4mg 8mg 8mg 8mg 8mg 12mg 12mg 12mg 12mg
Dose Number: 1 2 3 4 5 6 7 8 9 10 11 1212 Weeks T reatmentScreening
Lead in
Follow up
Early Termination1 week
1 week
4 weeks
Visit        1        2                3                4 5       6   (7T) 8  (9T) 10a801bET
T = T elephone Visit;   Visit 801 =  End of Study Visit;   ET = Early T ermination Visit
a =  Visit [ADDRESS_1152401] dose (Dose 12) of study drug.
b =   Visit 801 (follow up visit) occurs 4 weeks after Dose 12 or 3 weeks after Visit 10.
Figure GPG F.1. Illustration of study design for clinical protocol I8F -MC-GPG F.
I8F-MC-GPGF Cli nical Protocol Page 20
LY3298176Study Period I (Screening and Lead -In):
Screening (Visit 1)
Throughout the study , patients treated wi th metformin will remain on the same dose they  were 
receiving at Visit 1 unl ess changes need to be made for safet y reasons .  All pat ients will be 
encouraged to maintain their prestudy  diet and exerci se levels through the course of the study .
The purpose of screening procedures at Visit 1 is to establish init ial eligibilit y (seeSection 6)and 
to obtain blood samples for laboratory  assessments needed to confirm eligibilit y.  Patients who 
meet all applicable inclusio n criteria and none of the applicable excl usion criteria at Visi t 1 will 
continue on toVisit 2.
Lead -In (
Visit 2 to Visit 3)
During the l ead-in period, eligible pat ients should continue their prestudy therapy , metformin 
(sam e formulation and dose), in order to allow reliable assessment of HbA1c at baseline 
(Visit3).  During the lead-inperiod, pati ents will  be trained on disease monitoring and disease 
management procedures , gluco meter use, study  diaries, and study  procedures.  Patients will 
receive training on routine blood glucose monitoring and paper diary co mpletion required during 
the study .  Pati ents shoul d follow the invest igator’s instructions related to frequency o f blood 
glucose testing but sh ould test thei r glucose a minimum of [ADDRESS_1152402] (SMBG) prior to randomizat ion 
(Visit 3) and return the resul ts in thei r diary at Vi sit 3 (see Section [IP_ADDRESS] ). Patients willalso
receive educat ion on how to dilute study  drug in the vials,perform SCinject ions, appropriate 
inject ion site locations, inject ion techni que, and the si gns and symptom s of l ocal adverse 
reacti onsincluding inject ion site react ions.  Patients will receive instructions on timing of doses
(Table GPGF .3and Section 7.1), and will be instructed to record the date and time of all 
inject ions administered throughout the study  in their study  diaries.   Study  site staff will  observe 
each patient diluting the study drug vi als and self-inject ing for training purposes at all site visits 
beginning with Visit [ADDRESS_1152403] 
study  visit (see Schedule of Activities, (Section 2).  Patients should be instructed to record all 
AEs in their diaries .
Study Period II (Treatment Period) :
Randomization (Visit 3)
At Visit 3, patients will undergo study procedures that are required prior to randomizat ion.
Patients who con tinue to be eligible will then be rando mized in a 1:1:1:1 ratio to 1 of the titration 
schemes (Group 1, Group 2, or Group 3 ) or pl acebo.  Placebo p atients will be distributed within 
each ti tration group in order to m aintain treatm ent blinding.  A fter randomizat ion, the pati ent will 
dilute the study  drug vial  and inject the first dose of study drug while at the study  site.  Alt hough 
patients will  be diluting study  drug and inject ing themselves at home between study  site visi ts, 
they will be requi red to dilute the vials and inject themselves under the supervisio n of site 
I8F-MC-GPGF Cli nical Protocol Page [ADDRESS_1152404] scheduled dose level of LY3298176 . 
Treatment Phase (Visit 3 toVisit 10)
During the treatm entphase, t he dose of LY3298176 will be escalated within each ti tration group 
according to 1of 3dose titration schedules as outlined in Figure GPG F
.1.  
At each dosing time point, the study  drug will be self-administered as 1to [ADDRESS_1152405] acebo (number of inject ions will be determined by [CONTACT_830357]) (see Section 7.1).  
The l ast treatm ent visi t, Visit10, will occur approximately  [ADDRESS_1152406] ivities 
(Secti on2).  
Patients taking a stable dose of met formin at study  entry  will continue to use concomitant 
metformin throughout the treatment period .  Discont inuat ion or changes to dose are generally not 
permitted, except in the situat ions of patient safet y (for further details ,seeSection 7.1)
.
Patients will  be instructed to perform fasting blood glucose ( FBG ) measurements and to record 
all results in diaries; these results will be used for gl ucose m anagement only .  
Patients who develop severe , persi stent hy perglycemia based on pre specified thresho lds (see 
Secti on9.[IP_ADDRESS] )will receive a new glucose -lowering intervent ion(or rescue therapy )based on 
clinical judgment of the invest igator ,and the pati ent will discont inue study  drug .  Patients who 
need rescue therapy  for thi s reason will be asked to remain in the trial unt il they co mplete all 
study  visits for collect ion of safet y information.  Patients who discont inue study  drug due to AEs 
will also be asked to continue in the trial for collecti on of  safet y information.  Patients who are 
unable or unwilling to con tinue in the study  because of an AE or any  other reason will perform 
I8F-MC-GPGF Cli nical Protocol Page 22
LY3298176an early  terminat ion (ET) visit as their final study  visit.  If the pati ent is discont inuing during an 
unscheduled vi sit, that vi sit shoul d be perform ed as the ET vi sit.  If the pati ent is discont inuing 
during a scheduled visit, that visit should be considered the ET visit.  At this visit, patients will 
perform  procedures listed in the Schedule of Act ivities (Secti on2).
Study Period II I(Safety Follow -Up, Visit 801):
All rando mized pat ients who com plete the treatm ent peri od will complete the safet y follow-up 
approximately  [ADDRESS_1152407] visit (see 
Secti on9.9).
5.2. Number of Participants
Approximately  [ADDRESS_1152408] scheduled visit shown in the Schedule of 
Activities (Secti on2)for the last pat ient.
5.4. Scientific Rationale for Study Design
Study  GPGF is a 3-monthPhase [ADDRESS_1152409] dos e of 2.5 mg may 
improve tolerabilit y of higher doses; thus, a 2.[ADDRESS_1152410] LY3298176 dose level of 12 mg.  The 
12mg dose was chosen in order to compare the tolera bility and efficacy  of 12 m g with 15mg.  
The 12mg dose may provide efficacy similar to that of the 15 mg dose but with superior 
tolerabilit y, and this titration scheme provi des additi onal data f or dose and dose titration 
decisio ns for Phase 3.   Efficacy, safety,and tolerabilit y data fro m both Study  GPGB and Study  
GPGF will be used to set doses and the titration scheme for the Phase 3 development program.
I8F-MC-GPGF Cli nical Protocol Page 23
LY3298176The current study  will enroll patients wi th inadequate glycemic control based on HbA1c values 
ranging from 7 .0% to 10.5%, inclusive.  Similar ranges of screening HbA1c have been used in 
numero us studies of T2DM treatments.
Patients treated with diet and exercise alone, or in combinat ion with stable met formin 
monotherapy (1000 mg/day) , will be enrolled.  Patients on a second oral antihyperglycemic 
medicat ion(OAM) may also be eligible if the second OAM was discont inued 3months prior to 
Visit1 (refer to Section 6.2,Exclusio n Cri terion35).  Stable metformin treatment for at least 
3monthsis required to minimize glucose variability prior to s tudy entry .
5.5. Justification for Dose
The highest dose to be evaluated in Study  GPGF is [ADDRESS_1152411] dose being 
evaluated in the Phase 2 study  GPGB.   Depending on the safety , tolerabili ty,and efficacy data in 
Study  GPGB, the LY3298176 15 m g dose may be the high dose tested in the Phase 3 program.   
The 15 mg dose was considered safe in the Phase 1 study  GPGA although not well tolerated
.  
Based on experience with other GLP -1 RAs, higher doses m ay be attained through dose titrat ion 
to minimize GI -related AEs. The 3titration schemes to reach either LY3298176 12 m g or 15 m g 
were selected based on the fo llowing:
Phase [ADDRESS_1152412] week, and 15 mg the 
fourth week showed that this titration scheme to reach 15 mg was too rapid and resulted 
in more incidents of vomiting following the 15 m g dose than had been observed wit h 
other ti tration schemes wit h lower LY3298176 doses .  Thus ,a more gradual  titration may 
be needed to reach 15 mg.
The current titration schem e for Study  GPGB is LY3298176 [ADDRESS_1152413] 15 mg dose at Week 7, and 
continuing on 15 mg for the duration of the study .  Thi s titration scheme is expected to be 
tolerated ;however ,other titration schemes m ay have improved tol erabilit y or pati ent and 
physician convenience.  This will be explored in different ti tration schemes in Study 
GPGF .
Itis possible that a slightly lower dose ( >10 m g but <15 m g) woul d have improved 
tolerabilit y with comparable efficacy compared with 15 m g.  Therefore, LY3298176 
12mg was chosen as thehigh dose for 1 ti tration scheme.  
I8F-MC-GPGF Cli nical Protocol Page 24
LY32981766.Study Population
Prospective approval o f protocol  deviati ons to recrui tment and enro llment criteria, also known as 
protocol  waivers or exempt ions, are not permitted.
6.1. Inclusion Criteria
Patients are eligible to be included in the study  only  if they  meet all  of the f ollowing criteria at 
screening:
Type of Patient and Disease Characteristics
[1] Have T2DM for at least 6 months before screening based on the disease 
diagnosti c criteria ( Appendix 5 ).
[2] Have an HbA1c value at screening of 7.0% and 10.5% and treated with diet 
and exercise alo ne or a stable dose of m etformin (either immediate release or 
extended release, 1000 mg/day and not m ore than the l ocally approved dose )
for at least3months prior to screening /Visi t 1.  
Patient Characteristics
[3]Male or female pat ients 18 to 75years of age, inclusive .
[3
a]Male pati ents:
Male patients should be willing to use reliable contraceptive methods 
throughout the study  and for at l east [ADDRESS_1152414] injection (see 
Appendix 6 ).
[3
b]Female pat ients:
Women not of child -bearing potenti al may  parti cipate and include those 
who are:
infertile due to surgical sterilizat ion (hysterectomy, bilateral oophorectomy, 
or tubal ligation), congenital ano maly such as m ulleri an agenesis; or
postm enopausal –defined as 
oA wo man at l east [ADDRESS_1152415] 1 year ;or
oat least 6 m onths of spontaneous amenorrhea with a fo llicle -stimulat ing 
horm one (FSH) >40 mIU/mL; or
oA wo man [ADDRESS_1152416] 
6months of spontaneous amenorrhea; or
oA wo man at l east 55 years of age with a diagnosis of menopause pri or to 
starting horm one replacement therapy .
Women of child -bearing potenti al (not surgically sterilized and between 
menarche and 1 -year postmenopausal) may participate.  In order to 
participate, they must:
I8F-MC-GPGF Cli nical Protocol Page 25
LY3298176Women of child- bearing potenti al who are abst inent (if this is co mplete 
abstinence, as their preferred and usual lifest yle) or in a same sex 
relationship (as part of their preferred and usual lifest yle) must agree to 
either rem ain abst inent or stay in a same sex relat ionship wit hout sexua l 
relationships wit h males.
Otherwi se, women of child -bearing potential participat ing must agree to use 
1highly effective method ( <1% failure rate) of contraception, or a 
combinat ion of 2effect ive methods of contraception for the ent irety of the 
study :
oWomen of child -bearing potenti al must test negative for pregnancy  prior 
to init iation oftreatm ent as indicated by  a negat ive serum pregnancy test 
at the screening visit and followed by  [CONTACT_830358] 24 hours pri or to exposure. (Any pregnancy  testing subsequent to 
this initial test shoul d be based on compound specific concerns and is 
notmandated by  [CONTACT_830359] .)
oEither 1highly effect ive method of contraception (such as combinat ion 
oral contraceptives, implanted con tracepti ves, or intrauterine device) or 
a combinat ion of 2effective methods of contraceptio n (such as male or 
female condo ms with spermicide, diaphragms wit h spermicide ,or 
cervical sponges) will be used. The subject may choose to use a double 
barrier m ethod of contra ception. Barri er protecti on methods wi thout 
concomitant use of a spermicide are not a reliable or acceptable method. 
Thus, each barrier method must include use of a spermicide. Itshoul d 
be noted that the use of male and female condoms as a double barri er 
method is not considered acceptable due to the high failure rate when 
these m ethods are combined.
Not be breastfeeding.
[4] Have a body  mass index ( BMI )between 23and 45kg/m2(inclusive) at 
screening.
Informed Consent
[5] In the invest igator’s opi[INVESTIGATOR_3078] n, are well mot ivated, capable, and willing to:
prepare (with assistance if necessary) study  medicati on
self-inject (with assistance if necessary) up to 3injections each week
complete study  diary (ies), as requi red for thi s protocol
are receptive to continuing their prestudy  diet, activi ty levels, and fo llow 
simple dietary  advice as appropriate
perform  SMBG using the provi ded gl ucose meter.
[6] Be willing to maintainmetformin dose during the trial , if taking a stable 
dose of met formi
nat study  entry .  Pati ents experi encing hypoglycemia 
during the study  may have thei r metf ormin dose reduced.
I8F-MC-GPGF Cli nical Protocol Page 26
LY3298176[7] Are reliable and willing to make themselves available for the duration of the 
study , and who will com ply with the requi red study  and dosing vi sits and 
abide by  [CONTACT_830360].
[8]Are able and willing to give signed informed consent and h ave given wri tten 
inform ed consent to parti cipate in thi s study  inaccordance wi th local 
regul ations andthe ethi cal review board (ERB) governing their site.
6.2. Exclusion Criteria
Patients will  be excluded from  study  enro llment if they meet any o f the following cri teria at 
screening:
Medical Conditions
[9] Have t ype1 diabetes m ellitusor latent autoimmune diabetes in adults.
[10] Have uncontrolled diabetes defined as an epi[INVESTIGATOR_830351].
[11] Have had anepi[INVESTIGATOR_66677], as defined by [CONTACT_830361] c symptom s requi ring the assistance of another person for 
recovery , within 6 months pri or to Visit 1, or ha vea history  of hypoglycemia 
unawareness or poor recognit ion of hypoglycemic symptoms.  Any pat ient 
that the investigator feels will not be able to communicate an understanding of 
hypoglycemic symptoms and the appropriate treatment of hypoglycemia 
shoul d also be excluded.
[12] Have a history  of acute or chronic pancreat itis or elevat ion in serum 
lipase/amylase (greater than 2 times the upper limit of normal [ >2
ULN]) or 
fasting serum triglyceride level of >500 mg/dLat screening.
[13] Have a d iagnosis of gas troparesi s or hi story  of bariatri c surgery  or a clinically  
significant gastri c em ptying abnormalit y, in the opi[INVESTIGATOR_3078] n of the investigator.
[14] Have a ctive proliferat ive diabetic retinopathy.
[15] Have known liver disease, obvious clinical signs or symptoms of liver disease, 
acute or chronic hepat itis, or alanine aminotransferase (ALT) l evels > 2.5
ULN at Vi sit1, as determined by [CONTACT_21910] .
[16] Have a known self or family  history  (first-degree relat ive) of mult iple 
endocrine neopla sia type2A or ty pe2B, thy roid C-cell hyperplasia, or 
medullary  thyroi d carcino ma.
[17] Evidence of hypothy roidism or hy perthy roidism based on clinical evaluat ion 
and/or an abnormal thyro id-stimulat ing horm one that, in the opi[INVESTIGATOR_3078] n of the 
investigator, wou ld pose a risk to patient safet y.  Subjects on a stable dose of 
thyroid replacement therapy  for at least the prior 3 months who are clinically  
euthy roid and who are anticipated to remain on this dose throughout the trial 
periodmay be eligible if they meet the other cri teria.
I8F-MC-GPGF Cli nical Protocol Page 27
LY3298176[18] Have a screening calcitonin 20pg/mL as determined by  [CONTACT_830362] 1.
[19] Have had any  of the f ollowing within the last 6 months prior to screening:
myocardial  infarct ion (MI), unstable angina, coronary  artery  by[CONTACT_9292], 
percutaneous coronary  intervent ion (diagnostic angi ogram s are permitted), 
transi ent ischemic attack (TIA), cerebrovascular accident or decompensated 
congest ive heart failure , or currently  have [LOCATION_001] Health Associ ationClass 
IIIor IV heart failure. 
[20] Have an electrocardiogram (ECG) with abnormalities that may interfere with 
the interpretation of changes in ECG intervals at screening in the opi[INVESTIGATOR_3078] n of 
the invest igator.  A QTc (Fridericia) interval >450 ms in men and >470 msin 
women is specifically excluded.
[21] Known significant autonomic neuropathy  as evidenced by  [CONTACT_221040],
resting tachycardia, orthostati c hypotensio n, or diabet ic diarrhea.
[22] Have a p ersonal or family history  of long QT syndrom e, family history  of 
sudden death in a first -degree relat ive (parents, sibling, or children) before the 
age of 40years , or a personal history  of unexplained syncope within the last 
year.  Use of prescript ion or over -the-counter (OTC) medicat ions known to 
significant ly pro long the QT or QTc interval at screening is prohibited .
[23] Have poorly  controlled hypertension ( ie, mean seated systolic blood pressure 
[BP]160mmHg or m ean seated di astolic BP 95mmHg)at screening , or a 
change in antihypertensive medications within 30 days of screening, renal  
artery  stenosi s, or evi dence of labile BPi[INVESTIGATOR_830352].
[24] Random fasting triglycerides >500 mg/dL (5.7 mmo l/L).  If the patient is on 
lipid-lowering therap ies, doses must be stable for 30 days prior to screening.
[25] Have an est imated glomerular filtration rate (eGFR) < 45mL/min/1.[ADDRESS_1152417] meet local label requirements.
[26] Have a history  of atopy  (severe or m ultiple allergic manifestati ons) or 
clinically significant mult iple or severe drug allergies, or intolerance to topi[INVESTIGATOR_19529] l 
corticosteroi ds, or severe post -treatment hypersensit ivity react ions (including, 
but not limited to, ery thema m ultiforme maj or, linear immunoglobulin A 
derm atosis, toxic epi[INVESTIGATOR_194], anaphylaxis, angioedema, or 
exfoliative dermat itis).
[27] Have an act ive or untreated malignancy or have been in remission fro m a 
clinically significant malignancy (other than basal or squamous cell skin 
cancer, in situ carcino mas of the cervix, or in situ prostate cancer) for <5years
prior to screening .
I8F-MC-GPGF Cli nical Protocol Page 28
LY3298176[28] Have evidence of human immunodeficiency  virus (HIV) and/or posi tive HIV 
antibodies historically or at screening.
[29] Evidence of hepat itisB and/or posi tive hepat itisB surface ant igen or evi dence 
of active hepat itisC.
[30] Have a history  of a transplanted organ (corneal transplants [keratoplast y] 
allowed).
[31] Have evidence of a significant active, uncontrolled medical condit ion or a 
history  of any medical  problem  capable of const ituting a risk when taking the 
study  medicat ion or i nterfering wi th the inte rpretatio n of data, as judged by 
[CONTACT_221041].
[32] Have had a significant change in weight, defined as a gain or loss of at least 
5% body  weight in the 3 months prior to screening.
[33] Have had a blood donation of 450mL in the prior [ADDRESS_1152418] a hemoglo bin value <11 g/dL 
(males) or <10 g/dL (females), or any other condit ion known to interfere with 
HbA1c methodology .
[34] Have any other condit ion (including known drug or alcoho l abuse or 
psychiatric disorder) that, in the opi[INVESTIGATOR_1649] o f the investigator, may preclude the 
patient from following and co mpleting the protocol.
Prior/Concomitant Therapy
[35] Withthe exception o f stable doses of metformin, p atients on another OAM 
(including, but not limited to, sulfonylureas, dipeptidyl  pept idase -4inhibitor 
[DPP-
4i], sodi um–glucose cotransport 2 inhibitors, alpha -glucosidase 
inhibitors, meglit inides) in addit ion to m etformin therapy may be randomized 
if the addit ional OAM treatm ent was di scont inued at least 3months prior to 
screening.
[36] Have used insulin for diabet ic control with inthe prior year; however, short -
term use of insulin for acute condit ions is allowed ( 14days)in certain 
situations,such as during a hospi[INVESTIGATOR_221014] (see 
Secti on7.7)
.
[37] Have had any  exposure to GLP-1analogs or other related compounds within 
the prior 12months or any  history  ever of allergies to these medicat ions.  
Patients who previ ously took GLP -1 analogs or related compounds and who 
discontinued those medicat ions for intol erabilit y or lack of efficacy should not 
be randomized.
I8F-MC-GPGF Cli nical Protocol Page 29
LY3298176[38] Have been treated or plan to be treated with drugs that promote weight loss 
(eg, Saxenda [liraglut ide 3.0 mg], Xenical [orlistat], Merid ia[sibutramine], 
Acutrim [phenylpropanolamine], Sanorex [mazindo l], Api [INVESTIGATOR_82335]
[phentermine], BELVIQ [lorcaserin], Qsymia [phentermine/topi[INVESTIGATOR_830353]], Contrave [naltrexone/bupropi[INVESTIGATOR_2394]] or similar other body  weight 
loss medicati ons including OTC medications [ eg, allī]) wi thin 3 months 
prior to Visit 1.
[39] Are receiving chronic (>2 weeks) systemic glucocorticoid therapy (excluding 
topi[INVESTIGATOR_2855], intraocul ar, intranasal, intra -articular, or inhaled preparations) or have 
received such therapy  within 4weeks immediately prior to screening.
[40] Are current ly taking a central nervous system stimulant ( eg, Ritalin-SR) 
with the excepti on of  caffeinated beverages at screening.
[41] Within [ADDRESS_1152419] received treatment with 
a drug that has not received regulatory  approval  for any  indicat ion.  If the 
previous study  drug has a l ong half -life, 3 months or 5 half -lives (whichever is 
longer) should have passed.
[42] Have an average weekly alcoho l intake that exceeds 21 units per week (males) 
and 14 units per week (females) [1 unit = 12 oz or 360 mL of beer; 5 oz or 
150mL of wine; 1.[ADDRESS_1152420] illed spi[INVESTIGATOR_17040] s].
[43] Evidence of regular use of known drugs of abuse in the opi[INVESTIGATOR_3078] n of the 
investigator.
Prior/Concurrent Cli nical Trial Experience
[
44] H ave previously co mpleted or withdrawn fro m this study  or any  other study  
investigat ingLY3298176 .
[45]Previous exposure or known allergies to LY3298176.
[46] Are current ly enrolled in any other clinical trial invo lving an inve stigational 
product or any  other type of medical research judged not to be scient ifically or 
medically co mpat ible with this study
.
Other Exclusions
[47] A re invest igator site personnel directly affiliated wit h this study  and/or thei r 
immediate families.  I mmediate family is defined as a spouse, parent, child, or 
sibling, whether bio logical or legally adopted .
[48]
Are Eli Lilly and Co mpany empl oyees or are em ployees of any  third party  
involved in study  who requi re exclusio n of their emplo yees.
[49]Are, in the opi[INVESTIGATOR_3078] n of the invest igator or sponsor, unsuitable for inclusio n in 
the study .
I8F-MC-GPGF Cli nical Protocol Page 30
LY32981766.3. Lifestyle Restrictions
Study  parti cipants shoul d be instructed not to donate blood or blood products during the study  or 
for 60days following the study .
6.4. Screen Failures
Individuals who do not meet the criteria for participation in this study  (screen failures) may be 
rescreened only once at the discret ion of the investigator.  Before rescreening is performed, the 
patient m ust si gn a new informed consent form (ICF) and receive a new ident ification number.   
If, in the opi[INVESTIGATOR_3078] n of the invest igator, an ineligible lab test result is the result of an error or 
extenuat ing circumstance, then that parameter can be retested once (if feasible wit hin the t ime 
constraints of the screening p eriod) wi thout the patient having to be rescreened.   However, 
screen failures for HbA1c may not be retested or rescreened.
I8F-MC-GPGF Cli nical Protocol Page [ADDRESS_1152421] dose attained, 12 mg or 15mg, patients will receive 
3injections per week (to be taken at th e sam e time) .  Each SC dose administration of study  drug 
shoul d be in different quadrants of the abdomen. If the recommendat ion following the first 
interim analysis o f Study  GPGB is to l ower the highest dose of [ADDRESS_1152422] titrated LY3298176 dose for Groups 1 and 
2 will be 12.5 mg.
This study  will involve dose ti tration in 2.5 m g, 4 mg, 5 m g, or 7.5 m gdose increments 
(Table GPGF .3).  Al though the invest igators and patients will know which titration group the 
patients are assigned, they  will not know whether they are receiving LY3298176 or a 
complementary  volume o f placebo.
Patients will  be requi red to dilute study  drug in the vials and administer inject ions of the study  
drug or matching placebo at approximately the same time each week. The study  site will  send 
vials, diluent (Sterile Water for Injection ), and syrin geswith needles home with pat ients.  
For all 
clinical site visits, the patient should dilute the vials and administer the study  drug at the clinical 
research site under the supervisio n of study  personnel in order to reinforce patient understanding 
and confidence.  Patients will be dilut ing study  drug in the vials and self -inject ing at home 
during weeks without a clinical site visit and instructions will be provided.  The invest igator or 
site staff may assist patients with vial reconst itution and study  drug inject ion any  time they  deem  
necessary .
I8F-MC-GPGF Cli nical Protocol Page 32
LY3298176Table GPGF .3. Study Treatments and Dose Titration
Study PhaseRandom -
ization Treatment Phase
Visit 3 4 5 N/S 6 N/S N/S N/S 8 N/S N/S N/S
Week 0 1 2 3 4 5 6 7 8 9 10 11
Dose number 1 2 3 4 5 6 7 8 9 10 11 12
Titration schemes   (dose in mg)
Group 1 2.5 2.5 5 5 10 10 10 10 15 15 15 15
Group 2 2.5 2.5 2.5 2.5 7.5 7.5 7.5 7.5 15 15 15 15
Group 3 4 4 4 4 8 8 8 8 12 12 12 12
Abbreviation:  N/S= none scheduled .
Note:  For each of the groups, visits are scheduled to occur on the day of the next scheduled titrated dose.  For non -
scheduled visits, it is expected that the patient will dilute study drug and self-inject at home.  However, the 
investigator may have the patient come to the sit e for an unscheduled visit to dilute the vials and self-inject at any  
time the investigator feels that the patient would benefit from added instruction and supervision.  Visit 10 (not 
shown) will occur [ADDRESS_1152423] dose of study drug (Dose 12).
Patients taking background metformin (eit her immediate release or extended release) are 
strongly  encouraged to remain on the same ty pe of metformin during the trial, if possible.  
Changing formulat ions or m anufacturers of metformin during the study  parti cipation shoul d be 
minimized.  If a dose change (ie, conversio n of extended release to immediate release or vice 
versa) is required, the invest igator should determine the most appropriate clinically equivalent 
metformin dose.  The metformin dose should be at least 1000 mg/day and not more than the 
highest dose allowed per local label.
The patient receiving met formin should cont inue the baseline dose of met formin, unless the 
patient experiences documented hypoglycemia, in which case the dose may  be reduced.
Theinvest igator or his/her designee is responsible for the fo llowing:
explaining the correct use of the investigational agents to the patient or the pati ent’s legal 
representative
verifying that instructions are fo llowed properly
maintaining accurate records of investigational product dispensing and co llection
at the end of the study  returning all unused medication to Lilly ,or its desi gnee ,unless the 
sponsor and sites have agreed that all unused medication is to be destroy ed by [CONTACT_779], as 
allowed by  [CONTACT_1769].
Patients will  be instructed to contact [CONTACT_221043] /she has a com plaint 
or probl em with the study  drug so that the situation can be assessed.
7.1.1. Packaging and Labeling
Clinical trial materials will be labeled according to t he regulatory  requi rements.   LY3298176 and 
the matched placebos will be supplied by [CONTACT_11007].   
CCI
I8F-MC-GPGF Cli nical Protocol Page [ADDRESS_1152424] igator.   
  The reconstituted LY3298176 or placebo solut ion shoul d be 
used immediately after reconsti tution.
Study  drug mustbestored inarefrigerator at 2 C to 8C (36  F to 46F).  Temperature logsmust 
bemaintained toverify correct storage conditions at the investigator site, throughout thestudy. 
Patients shoul d be instructed to store the study  drug in their refrigerator but are not required to 
maintain temperature logs.   Sterile water vials may be stored at room temperature.
7.1.2. Medical Devices
The m anufactured medical devices provided for patient use in the study  are glucose m eters and 
lancet devices .
7.2. Method of Treatment
Assignment
A unique 4- digit pati ent number will be assigned to each pat ient when the patient signs the ICF.
Patients will be assigned to placebo or [ADDRESS_1152425] ive treatment 
arms via IWRS using the fo llowing stratificat ion vari ables: baseline HbA1c (<8.5%, 8.5%), 
metformin use (Yes, No), and BMI (<30, 3
0).  There will be approximately an equal  
rando mizat ion to the treatment arms (1:1:1:1).  
The rando mizat ion algori thmwill be perform ed using IWRS that will ensure balance between 
treatm ent arm s.
7.2.1. Selection and Timing of Doses
Assignment to [ADDRESS_1152426]’s case report form ( CRF )
.If a dose of 
study  drug, incl uding placebo, is missed, the patient should take it as soon as possible and 
contact [CONTACT_830363] .
7.2.2. Specific Restrictions/Requirements
Prior to beginning the study , pati ents will  com plete inform ed consent and baseline tests.
CCI
CCI
I8F-MC-GPGF Cli nical Protocol Page [ADDRESS_1152427] igator has deemed it safe to 
release the pati ent from the clinic.  There will be no inpatient stays.   
Meals/Diet – Patients shall fast for at least 8 hours overnight prior to each outpatient visit where
fasting samples are drawn or weight m easurements taken.
Alcohol –Alcoho l will not be permitted 8 hours prior to the dosing day, unt il the pat ient has 
been discharged from the clinical research site.
Exercise –Patients will be advised to maintain their r egular levels o f physical act ivity/exercise 
during the study .  When certain study  procedures are in progress at the site, patients may be 
requi red to rem ain recumbent or si tting.
Blood donation –Study  parti cipants shoul d be instructed not to donate blood or blood products 
during the study  or for 8weeks fo llowing the study .
Contraception –Male patients or thei r female partners of child -bearing potenti almust use 
reliable contraception during intercourse throughout the treatm ent peri od and for [ADDRESS_1152428] igator will know which dose 
titration group ( Group 1, Group 2, or Group 3) the patient is assigned to, they  will not know 
whether the patient is receiving LY3298176 or placebo.
To preserve the blinding of the st udy, a minimum number of Lilly  personnel  will see the 
rando mizat ion table and treatment assignments before the study  is complete.
Emergency  codes, generated by  a com puter drug -labeling system, will be available to the 
investigator.  These codes, which reve al thepatient’s treatment group when opened, may be 
opened during the study  ONLY if the patient’s well -being requires knowledge of the patient’s 
treatm ent assignment.
Emergency  unblinding for AEs may be perform ed through theIWRS , which m ay supplement or 
take the place of emergency  codes generated by  a com puter drug -labeling system.  This option 
may be used ONLY if the patient’swell-being requires knowledge of thepatient’streatm ent 
assignment.  All calls result ing in an unblinding event are recorded and reported by  [CONTACT_8784] .
If an invest igator, site personnel performing assessments, or patient is unblinded, the patient
must be discont inued fro m the study .  In cases where there are ethical reasons to have the patient
I8F-MC-GPGF Cli nical Protocol Page [ADDRESS_1152429] obtain specific approval fro m a Lilly clinical research 
physician (CRP) /clinical research scient ist (CRS) for the patientto continue in the study .
In case of an emergency , the invest igator has the sole responsibilit y for determining if unblinding 
of a pati ent’s treatm ent assignment is warranted for medical management of the event .  Patient 
safet y must al ways be the first considerat ion in making such a determinat ion.  If a patient’s 
treatm ent assi gnment i s unblinded, Lilly  must be notified immediately .  If the invest igator 
decides that unblinding is warranted, it is the responsibilit y of the investigator to prom ptly 
docum ent the decisio n and rat ionale and notify Lilly as soon as possible .  
Upon com pletion of the study , all codes m ust be returned to Lil ly or its designee .
7.4. Dosage Modification
Generally, no adjustment in study  drug doses (LY3298176 or placebo) will be allowed.
However, if a pat ient is unable to tolerate a titrated dose for 2 weeks due to vomit ing or m oderate 
to severe nausea, the site should call the study  CRS/CRP to di scuss whether the patient should 
have the dose lowered to the previous dose level.  Dosing o f requi red concomitant m etformin is 
discussed in Section 7.7.
The highest dose of Groups [ADDRESS_1152430] interim analysis of the large Phase 2 study  GPGB 
indicates that the 15 mg dose is not well tolerated.  In that case, sites will be informed at the 
start-up meet ing and in training materials.  Patients will be provided dosing instructions for the 
12.5 m g dose rather than the 15 mg dose.
7.5. Preparation/Handling/Storage/Accountability
The study  site must store the study  drug in a l ocked and secure environment. The study  drug 
must be refrigerated (not frozen) at 2 C to 8 C. Dry ice shoul d not be used for cooling. Patients 
will be provided with double -blinded vials containing lyophilized LY3298176 or pl acebo and 
Steril e Water for Inj ection (along wi th syringes) , at clinic visit s according to the Schedule of 
Activities(Secti on2).The patients will also receive insulated bags wit h cooling gel packs for 
use in transporting the study  drug from  the si te to the hom e. Study  drug in each parti cipat ing 
country  will be labeled according to the country’s regulatory  requi rements.
Commercial metformin may be made available during the treatment period to patients who 
entered the trial on this agent. Appropriate use and storag e information will be available by 
[CONTACT_221044].
7.6. Treatment Compliance
During the study ,patients will  be asked to return their study  drug vials and com pleted diari esto 
the site so that th eir com pliance may  be assessed.
Patients who are significant ly noncom pliant will  be permanent ly discontinued from study
medicat ion.  A pati ent will  be considered significant ly nonco mpliant if he /she misses 2 doses of 
study  medicat ion.  Similarly , a pati ent will  be considered significantly nonco mpliant i f he/she is 
I8F-MC-GPGF Cli nical Protocol Page [ADDRESS_1152431] intent ionally or repeatedly taken more or lessthan the 
prescribed amount of medication.
7.7. Concomitant Therapy
Treatment with drugs that are excluded in the entry criteria (Section 6.2) is not permitted.
The only conco mitant antihyperglycemic medicat ion permitted during this study  is met formin, 
unless glycemic criteria for rescue therapy  are m et (see Section7.8.1 )
.  Metformin treatment 
must be stable for at least 3monthsprior to screening at a daily dose of 1000 mg/day .  Pati ents
who enter the study  on di et and exercise alone will not be allowed to init iate metformin therapy  
after study  entry  unless cri teria for rescue therapy  are met.
Patients who are being treated with met formin upon entering this study  shoul d rem ain on the 
same (or equivalen t if switching to sustained release) met formin dose throughout the course of 
the study unless a change in dose is required to protect patient safet y.
If a patient switches fro m the immediate -release formulation o f metformin to the 
sustained -release formulation, the change will be on a milligram -per-milligram basis.
In certain situat ions (such as during a hospi[INVESTIGATOR_221014]), i t may be necessary  for 
a pati ent to be treated with insulin(s).  Treatment with insulin will be allowed for up to 
14consecutive days prior to or during the trial.  If a patient requires treatment with insulin for 
>14 consecutive days, that patient will be considered a “rescue” pat ient and m ay remain in the 
study  but will  not receive addi tional study  drug.
Doses o f antihypertensive and lipid- lowering therapi [INVESTIGATOR_221015] [ADDRESS_1152432] pati ent safety on an emergency  basis ( eg, hypertensive 
crisis).
Doses of other prescript ion medications ( eg, thyroxine, estrogen or progesterone replacement, or 
select ive estrogen receptor modulators) for treatment of concurrent medical condit ions shoul d 
remain constant durin g the study  whenever possible.
If the need for addit ional conco mitant m edicat ion arises, the patient may  be continued in the 
study  on study  medicat ion if, in the invest igator ’s opi[INVESTIGATOR_3078] n, the addit ion of the new medication 
does not pose a safet y risk.If an addit ional concomit ant m edicati on is started, the sponsor 
shoul d be informed as soon as possible. Nausea and/or vomit ing during this study  may be 
treated with ant iemetics but shoul d not be used prophylact ically.  Nonsteroidal anti -inflammatory  
medicat ions (including ibuprof en, aspi[INVESTIGATOR_248] ),acetaminophen, cough suppressants, antihistamines, 
vitamin/mineral supplements, ant ibiotics, and topi[INVESTIGATOR_2855] o intments may be used on an as -needed 
basis without notifying the sponsor and are not restricted by [CONTACT_830364]. Any additional medicat ion used during the course of the study (including those not 
requi ring sponsor notificat ions)must be documented on the appropriate electroni c case report 
form (eCRF) .
Specifically excluded concomitant medicat ions include thefollowing:
I8F-MC-GPGF Cli nical Protocol Page 37
LY3298176Chronic use of drugs that direct ly reduce GImotility including but not limited to 
anticholinergics, ant iemetics, and opi[INVESTIGATOR_858] ( eg, metocl opramide, phenergan, dicyclo mine, 
and morphine)
Chronic use of medicat ions that directly promote mot ility (eg, bethanecho l and cisapride)
Prescri ption or OTC medications to promote weight loss
Systemic glucocortico id therapy of >14 consecut ive day s’ durati on (wi th the except ion of 
topi[INVESTIGATOR_2855], intranasal, intraocular, intra -articular, and inhaled preparations)
Central nervous system st imulants ( eg, Ritalin-SR)
Any drug, other than those provided in this study , that has not received regulatory  
approval .
7.8. Treatment after the End of the Stu dy
7.8.1. Special Treatment Considerations (Rescue Therapy)
Invest igators will be trained on how to apply decisio n criteria for the timing and method of 
intervent ion in patients who do not reach glycemic targets during the 12-week treatment period.  
An addit ional therapeut ic intervent ion shoul d be consi dered in pat ients who meet the fo llowing 
criteria:
The patients are fully co mpliant with assigned therapeutic regimen .
AND
In the absence of any  acute condi tion that rai ses blood glucose either of the fo llowing 
occurs :
oDuring the first [ADDRESS_1152433] -randomization: An average fast ing glucose level 
>270 mg/dL ( 15.0 mmo l/L) occurs over at l east a 2 -week period (a t least 
3values/week must be available) .
OR
oAny time after the first [ADDRESS_1152434] -randomizat ion:  An average fasting glucose 
level >
240mg/dL ( 13.3 mmo l/L) occurs over at least a 2 -week period (at least 
4values/week must be available).
If these condit ions are met ,then pat ients may begin treatm ent wi th another antihyperglycemic 
agent as determined by [CONTACT_9682].   If treatm ent wi th another antihyperglycemic agent is 
instituted, then study  drug shoul d be perm anent ly discontinued.   Pati ents may remain in the stu dy 
for safet y follow-up, but the date at which they begin rescue therapy  will be the last date for 
collect ion of efficacy  measures.
I8F-MC-GPGF Cli nical Protocol Page 38
LY32981768.Discontinuation Criteria
8.1. Discontinuation from Study Treatment
8.1.1. Permanent Discontinuation from Study Treatment
Discontinuatio n due to a hepatic event or liver test abnormality.   Patients who are 
discontinued fro m invest igational product due to a hepat ic event or liver test abnormalit y 
shoul d have addi tional hepatic safet y data collected via case report form ( eCRF).
Discontinuat ion of the invest igational product for abnormal liver tests should be
considered by [CONTACT_82378] a patient meets one of the fo llowing condi tions af ter 
consultation wit h the Lilly designated medical monitor :  
oAbnorm al liver tests or when a patien t meets one of the fo llowing condi tions:
ALT or aspartate aminotransferase ( AST )>8ULN
ALT or AST >5 ULN for >2weeks
ALT or AST >3 ULN and total bilirubin level >2 ULN or prothrombin 
time >1.5 ULN
ALT or AST >3ULN with the appearance of fat igue, nausea, vo miting, 
right upper -quadrant pain or tenderness, fever, rash, and/or eosinophilia 
(>5%)
Alkaline phosphatase (ALP) >3 ULN
ALP >2.5ULN and total bilirubin >2x ULN
ALP >2.5 ULN with the appearance of fat igue, nausea, vo miting, right 
quadrant pain or tenderness, fever, rash, and/or eosinophilia (>5%) .
Invest igator decision
oThe invest igator decides that the patient should be discontinued from the study  
medicat ion.
Any medicat ion for wei ght loss is given for >
1week .
Adverse event.
When any one of the following events occur, Lilly or its designee is to be alerted 
immediately:
oPancreat itis or pancreatic cancer (refer to Secti on9.[IP_ADDRESS] for details)
oeGFR <30mL/min /1.[ADDRESS_1152435] ion site reacti on or ≥[ADDRESS_1152436] ion
oAny nonfatal major CV events (refer to Section [IP_ADDRESS].6 for details)
oAny other treatm ent-emergent adverse event ( TEAE ),serious adverse event 
(SAE ),or clinical lysignificant l aboratory  value for whi ch the invest igator 
believes that permanent study  drug discontinuation is the appropriate measure to 
be taken.
I8F-MC-GPGF Cli nical Protocol Page 39
LY3298176If the patient, for any  reason (including protocol -mandated inst itution of  rescue therapy; 
see Section 7.8.1 ), requires treatment for >1week with another therapeutic agent that has 
been demo nstrated to be effective for treatment of diabetes.  Also, a change in dose of 
metformin is not allowed (except for incidences of hypoglycemia; see Section 7.1).  
However, a change to an equivalent dose strength from immediate- release to 
extended -release (or vi ce versa) form ulation is allo wed.
If the patient misses 2doses (consecut ive or not) of study medicat ion or intentionally o r 
repeatedly takes more than the prescribed dose of study  medicati on (see Sect ion9.3).
If the patient develops any exclusion criteria, such as pregnancy or nursing.
If study  drug i s permanently discontinued, the patient should remain in the study  if possible.
Patients di scontinuing fro m the invest igational product prematurely for any  reason shoul d 
complete adverse event and other fo llow-up procedures per Section 2(Sche dule of Act ivities), 
Secti on 9.2(Adverse Events), and Section 9.4(Safety) of this protocol.
8.1.2. Temporary Discontinuation from Study Treatment
After rando mizat ion, the invest igator may temporarily discont inue study  drug, for exam ple, due 
to an AE ( eg, nausea a nd vo miting), or a clinically significant laboratory  value.  If study  drug 
discontinuat ion is due to an AE, the event is to be followed and documented.  Every  effort 
shoul d be made by [CONTACT_830365], as soon as it is safe to do so.  The dates of study 
drug di scontinuati on and restart will be documented.  Patient noncompliance should not be 
recorded as temporary  discont inuat ion of study  drug on the eCRF .  If≥2doses of study  
medicat ion (consecut ive or not) are missed for any reason, then the patient should be 
perm anent ly discont inued fro m study  medicat ion.
In the event that the patient requires the discontinuation of the study  drug, he/she may continue 
participat ion in the study, attend all visits ,and undergo all protocol procedures ,and patient data 
from the time of discont inuat ion of study  drug will not be included in the primary  analyses.
After study  drug di scont inuat ion, pati ents m ay commence any st andard diabetes therapy  in line 
with local or regi onal standards of care, and as considered appropriate by  [CONTACT_17062].
8.1.3. Discontinuation of Inadvertently Enrolled Patients
If the sponsor or invest igator ident ify a pat ientwho did not meet enrollment cr iteria and was 
inadvertent ly enro lled, then the patient should be discontinued fro m study  treatm ent unless there 
are extenuat ing circumstances that make it medically necessary for the patient to continue on 
study  treatm ent.  If the invest igator and the spo nsor CRP/CRS agree it is medically appropriate 
to con tinue, the investigator must obtain documented approval from the sponsor CRP/CRS to 
allow the inadvertent ly enrolled patientto continue in the study  with or wi thout treatm ent wi th 
investigat ional produc t. Safet y follow up i s as outlined in Sect ion 2(Schedule of Act ivities), 
Secti on 9.2(Adverse Events), and Section 9.4(Safety) of the protocol.
I8F-MC-GPGF Cli nical Protocol Page 40
LY32981768.2. Discontinuation from the Study
Some possible reasons that may  lead to perm anent di scontinuat ion include the following:
Enrollment in any other clinical  trial involving an investigational product or enrollment in 
any other ty pe of medical research judged not to be scient ifically or medically co mpat ible 
with this study
Sponsor decision
oParti cipation in the study  needs to be stopped for medical, safet y, regul atory , or 
other reasons consistent with applicable laws, regulat ions, and Good Clinical 
Practice (GCP) .
Invest igator decisio n
oThe invest igator decides that the patient should be discontinued fro m the study .
Subject decisio n
oThe patient requests to be withdrawn fro m the study .
Patients di scont inuing fro m the study  prem aturely for any  reason shoul d com plete adverse event 
and other safet y follow-up per Secti on
 2(Schedule of Act ivities), Section 9.2(Adverse Events), 
and Sect ion 9.4(Safety) of this protocol.
8.3. Lost to Follow -Up
A pat ient willbe considered lost to fo llow-up if he /she repeatedly fails to return for scheduled 
visits and is unable to be con tacted by  [CONTACT_4145].  Site personnel are expected to make 
diligent attempts to contact [CONTACT_57986] a scheduled visit or were otherwise 
unable to be fo llowed up by  [CONTACT_4179].
Site personnel, or an independent third party, will attempt to collect the vital status of the patient 
within legal  and ethical  boundaries for all patients randomized, including those who did not get 
investigat ional product.  Public sources may  be searched for vi tal status informat ion.  If vital 
status is determined, this will be documented and the pat ient will not be considered lost to 
follow-up.
Lilly personnel will not be invo lved in any attempts to collect vital status informat ion.
I8F-MC-GPGF Cli nical Protocol Page [ADDRESS_1152437] ivities, wi th the study  procedures and their timing (including 
tolerance limit s for timing).
Appendix [ADDRESS_1152438] ion 2. 
9.1.2. Secondary Efficacy Assessments
The fo llowing secondary  efficacy measures will be collected at the times shown in Section2.
HbA1c target of <7.0% 
Body weight : Patients will be weighed on an electronic (digital) scale in a light hospi[INVESTIGATOR_830354] e time in the morning after an overnight fast and 
evacuat ion of any bowel and bladder contents ( seeAppendix 7 )
.  The scale’s 
perform ance will  be m onitored at l east m onthly using standard weights, and records of 
these assessments will be kept in the study  binder.
FBG 
Waist circumference:  Waist circumference should be measured at the midpo int between 
the lower m argin o f theleast palpable rib and the top of the iliac crest .  The patient
shoul d stand wi th feet cl ose together, arms at the side ,and body  weight evenly 
distributed, and should wear a hospi [INVESTIGATOR_105463] . The patientshoul d be relaxed, and the 
measurements should be taken at the end of a normal expi[INVESTIGATOR_1516].  The m easurem ent 
shoul d be repeated.  If the difference between the 2 measurements exceeds 1 cm, the 
2measurements should be repeated.
[IP_ADDRESS]. Exploratory Efficacy Assessments
Seven -point SMBG profiles consist ing of blood glucose measurements shoul d be obtained 
before each meal, approximately [ADDRESS_1152439] via eCRF the occurrence and nature of 
each patie nt’s preexist ing condit ions, including clinically significant signs and symptoms of the 
disease under treatment in the study .  In addi tion, si te personnel  will record any  change in the 
condi tion(s) and any  new condi tions as AEs. Investi gators shoul d recor d their assessment of the 
potenti al relatedness of each AE to protocol procedure orinvest igational product via eCRF.
The invest igator will interpret and document whether or not an AE has a reasonable possibilit y 
of being related to study  treatm ent, study  device, or a study  procedure, taki ng into account the 
disease, concomitant treatment, or pathologies.
A “reasonable possibilit y” means that there is a cause -and-effect rel ationship between the 
investigat ional product, study  device ,and/or study  procedure a nd the AE.
The invest igator answers yes/no when making this assessment.
In addit ion to records of observat ions made at specific t imes, unexpected signs and symptoms 
and conco mitant m edicati ons will be recorded in the clinical trial records throughout the study .
Planned surgeries and nonsurgical intervent ions should not be reported as AEs unless the 
underlying medical condit ion has worsened during the course of the study .
If a patient’s investigational product is discontinued as a result of an AE, study  site personnel 
must report this to Lilly or its designee via eCRF, cl arifying if possible the circumstances leading 
toany dosage modificat ions or discont inuat ionsof treatm ent.
I8F-MC-GPGF Cli nical Protocol Page 43
LY32981769.2.1. Serious Adverse Events
An SAE is any  AE from this study  that resul ts in one of th e following outcom es:
Death
Initial or prolonged inpat ient hospi [INVESTIGATOR_3094]
Alife-threatening experience ( ie, immediate ri sk of dying)
Persistent or si gnificant disabilit y/incapacit y
Congeni tal anom aly/bi rth defect
Considered significant by  [CONTACT_3203] r for any other reason .  Important medical events 
that may  not be immediately  life-threatening or resul t in death or hospi[INVESTIGATOR_3092] m ay 
jeopardi ze the pati ent or m ay require intervent ion to prevent one of the other outcomes 
listed in the definit ion above.  Exam ples of such medical events include allergic 
bronchospasm requiring intensive treatment in an emergency room or at home, blood 
dyscrasias or convulsions that do not result in inpatient hospi[INVESTIGATOR_3094], or the 
development of drug dependency  or dru g abuse .
When a condit ion related to the invest igational device necessitates medical or surgical 
intervent ion to preclude either permanent impairment of a body function or permanent 
damage to a body  structure, the serious outcome of “required intervention” will be 
assigned.
All AEs occurring after signing the ICF are recorded in the e CRF and assessed for serious 
criteria.  The SAE reporting to the sponsor begins after the patient has signed the ICF and has 
received invest igational product.  However, if an S AE occurs after signing the ICF, but prior to 
receiving invest igational product, the SAE should be reported to the sponsor as per SAE 
reporting requirements and t imelines (see Sect ion9.2)if it is considered reasonably possibly  
related to study  procedure.
Study  site personnel  must al ert Lilly or i ts desi gnee of  any SAE within [ADDRESS_1152440] igator 
awareness o f the event vi a a sponsor -approved method.  If alerts are issued via telephone, they 
are to be immediately fo llowed by[CONTACT_221048] n on study -specific SAE forms.  This 
24-hour notificat ion requirement refers to the init ial SAE information and all fo llow-up SAE 
information.
Pregnancy (during maternal or paternal exposure to invest igational product) does not meet the 
definit ion of an AE.  However, to fulfill regulatory requirements ,any pregnancy should be 
reported fo llowing the SAE process to collect data on the o utcome for both m other and fetus.
Invest igators are not obligated to actively seek AEs or SAEs in subjects once they have 
discontinued and/or completed the study  (the patientsummary eCRF has been com pleted).  
However, if the invest igator learns of any SAE , incl uding a death, at any  time after a subject has 
been discharged from the study , and he/she considers the event reasonably  possibly  related to the 
study  treatm ent or study  parti cipat ion, the invest igator m ust prom ptly notify Lilly .
[IP_ADDRESS]. Suspected Unexpected Serious Adverse Reactions
Suspected u
nexpected serious adverse reactions (S[LOCATION_003]Rs) are serious events that are not listed 
in the IB and that the investigator ident ifies as related to investigational product or procedure.  
I8F-MC-GPGF Cli nical Protocol Page [ADDRESS_1152441] ive 2001/20/EC and the 
associ ated detailed guidances or nati onal regulatory  requirements in parti cipat ing countries 
requi re the reporting of S[LOCATION_003]Rs . Lilly has procedures that will be fo llowed for the recording 
and expedited reporting of S[LOCATION_003]Rs that are consistent with glo bal regulat ions and the associated 
detailed guidances.
[IP_ADDRESS]. Adverse Events of Special Interest
The fo llowing a dverse events of special interest (AESIs) of varying clinical significance will be 
used to determine the tolerabilit y of LY3298176 over the range of doses selected for this clinical 
trial.  All  AESIs shoul d be captured and reported to Lilly  on the AEeCRF or on a specific eCRF, 
if applicable (see below).  Any AESI that meets the definit ion of an SAE (see Secti on9.2.1 ) 
must be reported as an SAE.
When any one of the following ev ents occur ,Lilly or its designee must be alerted immediately, 
whether it is assessed as an SAE or not:
Confirmed pancreat itis or pancreatic cancer
Any severe inject ion site reaction or [ADDRESS_1152442] ion site reactions occurring a 
week or more apart
Any study  drug -related hy persensi tivity react ion
Any other TEAE, SAE, or clinically significant laboratory  value for which the 
investigator believes that permanent study  drug di scontinuat ion is the appropriate 
measure to be taken.
[IP_ADDRESS].1. Nausea, Vomiting, and Dia rrhea
Nausea, vo miting, and diarrhea events will be recorded on a specific eCRF.  They  shoul d not be 
recorded as AEs unl ess the event m eetsanSAE criterion.  For each event ,assessment of severit y, 
durati on, and invest igator’s opi[INVESTIGATOR_3078] n of relatedness to st udy drug and protocol procedure will be 
captured.
[IP_ADDRESS].2. Injection Site Reactions
All injecti on si te reacti ons, including reports of pain and burning, and information regarding 
their time of day , time rel ative to inject ion, size, am ount of  erythema, indurat ion, and pruritus, as 
well as severit y, will be recorded on specific e CRFs.  In addit ion, if the react ion is clinically  
significant, the site shoul d attem pt to contact[CONTACT_830366]
-up procedures .  
Inject ion site reactions do not need to be recorded as AEs unless they  meet SAE criteria.
[IP_ADDRESS].3. Hypersensitivity Reactions
All hypersensit ivity react ions will be reported by  [CONTACT_82389], if any serious 
criterion is m et, as SAEs.  Study  drug shoul d be temporarily discont inued forany individual 
suspected of having a severe or serious allergic/hypersensit ivity react ion to study  drug.  Study  
drug m ay be restarted if, in the opi[INVESTIGATOR_3078] n of the investigator, the event was not related to study 
drug and when/if it is safe to do so.  If study  drug is perm anent ly discont inued, the patient should 
remain in the study .
I8F-MC-GPGF Cli nical Protocol Page 45
LY32981769.[IP_ADDRESS]. Hypoglycemia
Hypoglycemia epi[INVESTIGATOR_134055] a specific eCRF. Informat ion regarding severit y, 
time of day ,and invest igator’s opi[INVESTIGATOR_3078] n of relatedness to study drug and procedure will be 
recorded.  Hy poglycemia epi[INVESTIGATOR_221018].  Hy poglycemia will be classified as follows (American Diabetes Associat ion 2005) :
Documented Symptomatic Hypoglycemia:   Any time a patient feels that he/she is 
experiencing symptoms and/or signs associated with hy poglycemia and has a plasma 
glucose l evel of  3.9mmo l/L (70mg/dL) .
Asymptomatic Hypoglycemia: An event not accom panied by  [CONTACT_11017][INVESTIGATOR_82344] s of 
hypoglycemia, but with 3.9mmo l/L (70mg/dL) plasma glucose.
Severe Hypoglycemia: An epi[INVESTIGATOR_221019], glucagon, or other resuscitat ive act ions.  These e pi[INVESTIGATOR_1841] m ay be 
associ ated wi th sufficient neuroglycopenia to induce seizure or coma.  Plasma glucose 
measurements may  not be available during such an event, but neurological recovery  
attributable to the restoration of plasma glucose to normal is considered sufficient 
evidence that the event was induced by a low plasma glucose concentration.
Nocturnal Hypoglycemia:   Any hypoglycemic event that occurs between bedt ime and 
waking .
Probable Symptomatic Hypoglycemia: An event during which symptoms of 
hypoglycemi a are not accom panied by  a plasma glucose determinat ion (but that was 
presum ably caused by a plasma glucose concentratio n 3.9mmo l/L [70mg/dL]) .
[IP_ADDRESS].5. Acute Pancreatitis
Acute pancreat itis is defined as an AE of interest for this study. Acute pancreat itis is an acute 
inflammatory  process of the pancreas that may  also involve peripancreat ic tissues and/or remote 
organ sy stems (Banks et al. 2006) . The diagnosis of acute pancreatit is requires 2 of the 
following 3 features:
abdo minal pain, characterist ic of acute pancreat itis (generally located in the epi[INVESTIGATOR_693075] [Banks et al . 2006; Ko izumi et al. 
2006] ; the pain is often associated with nausea and vomit ing);
serum  amylase (total and/or pancreatic) and/or lipase 3ULN;
characterist ic findings of acute pancreat itis on computed tomography  (CT) scan or 
magnet ic resonance imaging (MRI).
If acute pancreat itis is suspected, appropriate laboratory  tests (including levels of pancreat ic 
amylase and lipase) should be obtained via the central laboratory  (and l ocally, if needed). 
Imaging studies, such as abdo minal CT scan with or without con trast, MRI, or gallbladder 
ultrasound, should be performed.  If laboratory  values and/or abdominal imaging support the 
diagnosis of acute pancreat itis, the patient must discontinue therapy wit h invest igational product ,
but will cont inue in the study  on another glucose -lowering regimen (see Sect ion7.8.1 for details 
on rescue intervent ion).  The most appropriate diabetes therapeutic regimen will be decided by 
[CONTACT_3170], based on the patient’s clinical status.  A review of the patient’s conco mitant 
medicat ions should be conducted to assess any  potent ial causal relat ionship with pancreat itis.
I8F-MC-GPGF Cli nical Protocol Page [ADDRESS_1152443] be reported. If typi[INVESTIGATOR_10926]/or symptoms o f 
pancreat itis are present and confirmed by [CONTACT_11018] (lipase or amylase [total and/or 
pancreat ic]) and imaging studies, the event must be reported as an SAE. For a potential case that 
does not m eet all of these criteria, it is up to the investigator to determine the seriousness of the 
case (AE or SAE) and the relatedness o f the event to study  drug.
In addit ion to the diagnostic assessment in patients who develop symptoms o f acute pancreatit is, 
each patient will have measur ements of pancreat ic amylase and lipase at screening, baseline, and 
during the study , including follow up, to assess any  potential  effects of LY3298176 on the 
exocrine pancreas (refer to Section 2, Schedule o f Activities).  Further di agnostic assessment per 
Lilly algorithm for assessment of asymptomatic pancreat ic hyperenzymemia will be required 
whenever lipase and/or pancreatic amylase are 3ULN at any time during the study .  If this 
situation occurs at Visit 801 (Week 15), the patient will be required to undergo this addit ional 
workup, and the data will be co llected in the clinical trial database.
All suspected cases of acute or chronic pancr eatitis, as well as cases of confirmed lipase or 
pancreat ic amylase values 3
ULN, will be adjudicated by [CONTACT_221050]. In addit ion, AEs of severe or serious abdo minal pain o f unknown et iology will also 
be submitted to th e adjudication co mmittee to assess for possible pancreat itis or other pancreatic 
disease. Relevant data from  patients wi th acute or chronic pancreat itis, those with severe or 
serious abdo minal pain, and those that undergo addit ional assessments due to con firmed 
hyperenzymemia will be entered into a specifically designed eCRF page by  [CONTACT_221051]. The adjudicat ion committee representative will enter the results of adjudicat ion in a 
corresponding eCRF page.
[IP_ADDRESS].6. Major Adverse Cardiovascular Events
Deaths (CV and non -CV), nonfatal MIs, supraventricular arrhy thmias, and nonfatal strokes that 
occur during the treatment period or follow -up period will be adjudicated by  [CONTACT_221052] a study -specific adjudicat ioncharter.  Investigative 
sites will also be asked to submit any  cases of TIA or hospi[INVESTIGATOR_221021].  Hospi[INVESTIGATOR_221022] (such as coronary  artery  by[CONTACT_221053]) will also be submitted for adjudicat ion.
Cardi ovascular event definit ions will be based on the Standardized Definit ions for 
Cardi ovascular and Stroke Endpoint Events in Cli nical Tri als (Hicks et al . 2015) and the 
ESC/ACCF/AHA/WHF Expert Consensus Document Third Universal Definit ion of Myocardial  
Infarct ion (Thygesen et al . 2012) .  An adjudicat ion committee will enter the results of 
adjudicat ion in the corresponding eCRF page .
[IP_ADDRESS].7. Thyroid C -Cell Hyperplasia and C -Cell Neoplasms
Individuals with personal or family history  of certain thyro id or nonthyro id endocrine 
abnorm alities or certain preexist ing laboratory  and genet ic characterist ics will be excluded fro m 
the study  (see Secti on6.2)
.  The assessment of thyroid safety  during the tri al will include 
reporting of thy roid TEAEs and m easurements of calcitonin according to Secti on2at screening
I8F-MC-GPGF Cli nical Protocol Page 47
LY3298176and Visit 10 (end of treatment ) or ET vi sit.  The purpose of cal citonin measurements i s to assess 
the potenti al of LY3298176 to affect thy roid C-cell function, which includes devel opment of 
C-cell hyperplasia and neoplasms.
Patients who devel op serum  calci tonin increases 50% of the mean of the screening values AND 
an abso lute value 20pg/mL and <35 pg/mL at Visit 10 (end of treatment ) or at ET will be 
asked to repeat the measurement within 1 month.  If this repeat value is increasing ( 10% 
increase), the patient will be encouraged to undergo additional endocrine assessment and longer
term follow
-up by  [CONTACT_221054] a seri ous adverse effect on the gland.
For pati ents who requi re addi tional endocrine assessment because of increa sed calcitonin 
concentration per criteria provided in this sect ion, data from the fo llow-up assessment will be 
collected in the specific section o f the eCRF.
9.2.2. Complaint Handling
Lilly co llects product complaints on invest igational products and drug delivery system s used in 
clinical studies in order to ensure the safet y of study  parti cipants, m onitor quali ty, and to 
facilitate process and product improvements.
Patients will  be instructed to contact [CONTACT_221043] /she has a com plain t 
or probl em with the investi gational product or drug delivery  system  so that the si tuation can be 
assessed.
9.3. Treatment of Overdose
For pati ents wi th suspected or confirmed overdose with LY3298176, there is no specific 
antidote.  The patient should be watch ed for GI symptom s and hypoglycemia.  Treatment is 
supportive, depending on the patient’s symptoms.
9.4. Safety
9.4.1. Electrocardiograms
For each patient, 12-lead ECGs shoul d be collected according to Secti on2. Patients must be 
supi[INVESTIGATOR_17044]  [ADDRESS_1152444] ion of more ECGs than expected at a pa rticular time point i s allowed when needed to 
ensure high -qualit y records.
Electrocardiograms will init ially be interpreted by  a qualified physician (the investigator or 
qualified designee) at the site as soon after the time of ECG collection as possible, and ideally  
while the patient is st ill present, to determine whether the subject meets entry criteria and for 
I8F-MC-GPGF Cli nical Protocol Page [ADDRESS_1152445] igationaltreatment s hould be reported to Lilly  or its designee 
as an AE .  The investigator (or qualified designee) is responsible for determining if any change 
in patient management is needed, and must document his/her review of the ECG printed at the 
time of evaluat ion.
After enro llment, if a clinically significant increase in the QT/QTc interval fro m baseline or 
other clinically significant quantitative or qualitat ive change fro m baseline is identified, the 
patientwill be assessed by [CONTACT_221055] ( eg, palpi[INVESTIGATOR_814], near syncope, and 
syncope) and to determin e whether the patientcan continue in the study .  The invest igator or 
qualified designee is responsible for determining if any change in patientmanagement i s needed 
and must document his /her review of the ECG printed at the time of evaluation fro m at least 1of 
the replicate ECGs from each t ime point.
All digital ECGs will be obtained using centrally  provi ded ECG m achines and will be 
electroni cally transmitted to a designated central ECG laboratory .  The central ECG laboratory  
will perform a basic qualit y control  check ( eg,demographics and study details) andthen store the 
ECGs in a database.  At a future time, the stored ECG data may be overread by a cardio logist at 
the central  ECG laboratory  for further evaluat ion of machine -read measurements or to meet 
regul atory  requi rements.
The m achine -read ECG intervals and heart rate may be used for data analysis and report -writing 
purposes, unless a cardio logist overread ingof the ECGs i s conducted prior to complet ion of the 
final study  report (in which case, the o verread data would be used).
In addit ion, for each patient, a single ECG will be recorded at screening and if the patient 
discontinues from  the study  prem aturely ( Secti on2) for immediate patient management. These 
ECGs will be stored at the invest igation site.
Any treatm ent-emergent clinically significant ECG finding result ing in a diagnosis shoul d be 
reported as an AE in the eCRF.
9.4.2. Vital Signs
Sitting BP and P R will be measured using standardized equipment provided by [CONTACT_456] .
Vital sign m easurements shoul d be taken before obtaining an ECG tracing
and before collect ion 
of blood sam ples for laboratory  testing, at vi sits where requi red (see Section2). The participant 
shoul d be requi redto sit quietly for 5minutes befo re vital sign measurements are taken. An 
appropriately  sized cuff (cuff bladder encircling at least 80% of the arm) should be used to 
ensure the accuracy  of BP m easurements.  The arm used for the BP measurement should be 
supported at heart level. At Visit1 (screening), to determine which arm shoul d be used to collect 
BP and PR throughout the study , BP and PR will be measured once in each arm, and the arm that 
had the higher systolic BP shoul d be used to collect all 3 measure ments of both BP and PR at all 
study  visits.  For each parameter (PR, systolic BP, and diastolic BP) , 
3measurements will be 
taken using the same arm ; the recordings should be taken at least [ADDRESS_1152446] ivities (Secti on2).
Any clinically  significant findings from laboratory tests that resul t in a di agnosis and that occur 
after the pati ent receives the first dose of invest igatio nal product should be reported to Lilly or its 
designee as an AE .
9.4.4. Safety Monitoring
Lilly will periodically  review evolving aggregate safet y data wi thin the study  by [CONTACT_82393] .  In addit ion, the study team will review safet y reports in a blinded fashion according to 
the schedule provided in the Trial -Level  Safety  Review plan.  Lilly will also revi ew SAEs wi thin 
time frames mandated by  [CONTACT_221056].  The Lilly  CRP/CRS will , as appropri ate, consult 
with the f unctionally  independent Gl obal Patient Saf ety therapeuti c area physician or clinical 
scientist.
In addit ion, specific s afety measures are included in the protocol to ensure appropriate 
monitoring of pancreat ic, thy roid, and liver safet y.  Laboratory  findings that trigger pancreat ic 
and thy roid safet y monitoring per Lilly standards are provided in Sect ions9.[IP_ADDRESS] and
[IP_ADDRESS].[ADDRESS_1152447] ion8.1.1 . If a 
study  patient experiences elevated ALT 3ULN or elevated total bilirubin 2ULN, clinical 
and laboratory  monitoring shoul d be ini tiated by  [CONTACT_3170].  Details for hepat ic monitoring 
depend upon the severit y and persistence o f observed labor atory  test abnorm alities.  To ensure 
patient safet y and com ply wi th regulatory  guidance, the invest igator is to consult with the Lilly 
CRP /CRS regarding collect ion of specific reco mmended clinical informat ion and fo llow-
up 
laboratory  tests (see Appendix 4 ).
9.5. Pharmacokinetics
Blood sam ples f or PK analyses will be collected from all rando mized patients in accordance wit h 
the Schedule of Act ivities(Secti on2) and at ET.  However, only samples from pat ients assigned 
to treatment with LY3298176 will be analyzed for drug concentration.
Date and time o f each sample and the most recent LY3298176 dose pri or to PK blood draw must 
be recorded.   Scheduled PK samples must be collected prior to dose administration at scheduled 
visits.
Drug concentration informat ion that would unblind the study  will not be reported to study  sites 
or blinded personnel wh ile the study  is blinded.
Bioanaly tical samples collected to m easure study drug concentrati on will be retained for a 
maximum o f 1year following the l ast pati ent visi t for the study .
I8F-MC-GPGF Cli nical Protocol Page [ADDRESS_1152448] ion, variabilit y of patient response (including safety ), and 
clinical outcome.  Sample co llection is incorporated into clinical studies to enable examinat ion of 
these quest ions through measurements of bio molecules, incl uding DNA, RNA, proteins, lipi[INVESTIGATOR_805], 
and other cellular el ements.
Serum  and plasma ethylenediaminetetraacetic acid (EDTA) samples for nonpharmacogenet ic 
biomarker research will be co llected at the times specified in the Schedule of Activit ies 
(Secti on2
) where l ocal regul ations allow.
Samples will  be used for research on the drug target, disease process, variable response to 
LY3298176, pathway s associ ated wi th diabetes, mechanism o f action of LY3298176, and/or 
research method or in validat ing diagnost ic tools or assay(s) related to diabetes.
Samples will  be retained for a m aximum  of 
15years after the last patient visit for the study ,or 
for a shorter peri od if local regulations and ERBs impose shorter time limit s, at a facilit y selected 
by [CONTACT_11007] .  This retention period enables use of new techno logies,respon seto regulatory  
questions, and invest igation of variable response that may not be observed unt il later in the 
development of LY3298176 or after LY3298176 becomes commercially available.
9.9. Health Economics
Not applicable.
9.10. Samples for Immunogenicity Research
Samples fro m all patients will be tested for antidrug antibodies (ADA) against LY3298176.  A 
blood sam ple will be collected at specific study  visits according to the Schedule of Act ivities
(Secti on2).  All samples for immunogenicit y should be taken predose when applicable.  To 
interpret the resul ts of immunogenicit y, a PK sample should be collected at the same time po int 
as an the immunogenicit y sample.  In the event of drug hy persensi tivity react ions (immediate or 
nonimmediate), additional samples will be co llected as close to the onset of the event as possible, 
at the resolut ion of the event, and [ADDRESS_1152449] and 
titer ADA in the presence of LY3 298176 at a l aboratory  approved by  [CONTACT_456]. Confirmed 
positivesamples for LY3298176 ADA will be titrated and then evaluated for cross -reactive 
binding to native GIP and GLP -1 using a validated ligand -binding assay . They  may also be 
tested for their abili ty to neutralize the activit y of assigned treatment (LY3298176 -neutralizing 
antibodies) in separate cell -based neutralizing assays over -expressing the GIP and GLP -[ADDRESS_1152450] 
LY3298176 and/or for cross -reacti ve binding to native GIP and GLP -[ADDRESS_1152451] an ADA sample measured at ETorat the follow-up visit (Visi t801) 
approximately  1monthafter the last dose of LY 3298176.  A risk-
based approach will be used to 
monitor pati ents who have clinically significant treatm ent-emergent anti drug ant ibodies (TE -
ADA) at the last visit .  Treatment -emergent ADA are defined as those with a titer 2 ‑fold 
(1dilution) greater than the minimum required dilution if no ADA were detected at baseline or 
those wi th a 4-fold (2 dilutions) increase in titer compared to baseline if ADA were detected at 
baseline. Clinically significant TE -ADA will be defined as any TE -ADA at the follow -up 
visit 
(Visit801) with
:
A high titer (1280) or an increasing t iterfrom last measured value
An associ ation of TE -ADA wit h a m oderate to severe injection site react ion or 
infusio n-related reacti on
Cross -reactive and/orneutralizing binding o f an ADA wit h endogenous GLP -[ADDRESS_1152452] returned to baseline ADA titer 
(defined as ADA t iter wi thin 2- fold of baseline).   A PK sample may be collected at the fo llow-up 
immunogenicit y assessment(s) if warranted and agreed upon between both the investigator and 
sponsor.
Every  attem pt shoul d be made to contact [CONTACT_830367]-up immunogenicit y assessment; 
however, if pat ients are unwilling or unable to return for the visit, this is not considered a 
protocol  violation.
Patients fo llowed f or at l east [ADDRESS_1152453] pati ent visi tfor the study , or 
for a shorter peri od if regulat ions and ERBs impose shorter time limit s, at a facilit y selected by  
[CONTACT_11007].  The durati on allows the sponsor to respond to future regulatory  requests related to 
LY3298176.   Any samples remaining after 15 years will be destroyed.
I8F-MC-GPGF Cli nical Protocol Page 52
LY329817610. Statistical Considerations
10.1. Sample Size Determination
Approximately  92patients will be rando mized to placebo or 1 of 3LY3298176 titrationsarms 
assuming a 13% dropout rate result ing in approximately 20completers per arm .
Assum inga standard deviat ion of 1. 1, [ADDRESS_1152454] 90% power to 
detect a statistically significan t difference between LY treatments to placebo with a dose 
response assumpt ion as shown in Table GPG F
.4.
Table GPG F.
4. Dose –Response Assumption Used in Sample Size Determination
Placebo LY 12 mg LY 15 mg-1 LY 15 mg-2
CFBL HbA1c (%) -0.2% 1.4% 1.5% 1.5%
Abbreviations: CFBL = change from baseline ; LY = LY3298176 .
10.2. Populations for Analyses
For purposes of analysis, the following populat ions are defined in Table GPG F.5.
Table GPG F.
5. Definitions of Populations to Be A nalyzed in Study GPG F
Population Description
Enrolled All participants who sign informed consent.
ITT (intention -to-treat) All randomized patients.
mITT (modified ITT) All randomized patients with at least 1 postbaseline measurement according to the 
treatment the patients were assigned.
PP (per -protocol) All randomized patients who were compliant with study drug and completed the protocol .
Safety All randomized participants who take at least [ADDRESS_1152455] ical analysis plan (SAP) and/or clinical study  report
(CSR) .  Addit ional exploratory  analyses of the data may  be perform ed as deemed appropriate.  
Analyses will be fully detailed in the SAP.
The intent ion-to-treat (ITT) populat ion is defined as all rando mized pat ients.  Stati stical analyses 
(including the primary analysis) will be conducted on the modified ITT (mITT) populat ion.  The 
mITT populat ion is defined as all rando mized pat ients with at least 1 postbaseline measurement 
according to the treatment the patients were assigned.  The per- protocol (PP) populat ion is 
defined as all rando mized patients who were compliant with study drug and completed t he 
I8F-MC-GPGF Cli nical Protocol Page [ADDRESS_1152456] 1 dose of study  drug.  Safet y analyses will be 
perform ed on the safet y populati on.
Some efficacy measures will also be analyzed on the PP dataset.  The PP analysis will include 
patients who meet the fo llowing addi tional criteria:
Have been appropriately rando mized
Have not discont inued fro m the study  for any  of the early  discontinuati on cri teria
Have not missed 2 doses during the treatment period
Have not been rescued or taken a concomitant ant ihyperglycemic medicat ion besides 
metformin for >7cumulat ive days during the treatment period .
Patients who have had rescue therapy  will be incl uded in the m ITT popul ation, but n ot the PP 
popul ation. The efficacy measures will be censored at the time o f rescue for analyses using 
mITT populat ion.
No adj ustments for multiplicity will be performed.
All tests of treatment effects will be conducted at a one- sided alpha level of 0.1 an d/or one -sided 
90% confidence interval, unless otherwise stated.
The baseline value used for the analyses will be the last scheduled baseline value obtained for 
each patient prior to randomization.
10.3.2. Treatment Group Comparability
[IP_ADDRESS]. Patient Disposition
All pati ents who di scont inue the study  will be i dentified, and the extent of their participation in 
the study  will be reported.  If known, a reason for their discont inuation will be given.  The 
primary  reasons for di scont inuat ion will be listed and will be summari zed by [INVESTIGATOR_24258].  The 
percentage of patients discontinuing fro m each treatment will be co mpared using the Fisher’s 
exact test.
[IP_ADDRESS]. Patient Characteristics
Dem ographic and baseline characterist ics will be summarized by [CONTACT_1570].  Categorical 
variables w ill be summarized by  [CONTACT_22977].  For categorical variables, 
comparisons between treatment groups will be assessed using a Pearson Chi -Square test.  
Continuous variables will be summarized by [CONTACT_221063].  For continuous variables, 
comparisons between the treatment groups will be performed using a [ADDRESS_1152457].
[IP_ADDRESS]. Concomitant Therapy
Listings and summary of conco mitant therapi[INVESTIGATOR_221023] .
[IP_ADDRESS]. Treatment Compliance
Treatment compliance will be listed using all randomized pat ients and summarized using the 
mITT populat ion.  For a given pat ient, overall co mpliance for treatment period is defined as not 
I8F-MC-GPGF Cli nical Protocol Page 54
LY3298176missing 2 doses of the assigned treatment at any  point in the study .  Pati ents who miss 2doses 
at any  point during the study  will be consi dered si gnificant ly nonco mpliant and will be 
perm anent ly discont inued fro m study  medicat ion.  These pat ients will not be included in the PP 
analysis.
10.3.3. Efficacy Analyses
[IP_ADDRESS]. Primary Analyses
The primary  outcom e is the difference in HbA1c change fro m baseline between treatment groups 
based on the mITT populati on at the pl anned e nd of the treatment period of 3 months .  The 
primary  analysis model will be a mixed model for repeated measur es(MMRM )for HbA1c 
change from baseline to 3 months in the mITT popul ation with treatm ent, visit, treatm ent-by-
visit,  baseline BMI category , and metformin use (yes, no) as fixed effects, andbaseline HbA1c 
as a covariate. The dependent variable will be the postbaseline change fro m baseline values.  An 
unstructured covariance structure will be used to model the within -patient errors. If this model 
fails to converge, the fo llowing covariance structures will be tested in orde r:
toeplitz with heterogeneit y
autoregressive with heterogeneit y, by [CONTACT_765]
compound symmetry  with heterogeneous variances by  [CONTACT_765] 
toeplitz
autoregressive
compound symmetry  without heterogeneous variances, by  [CONTACT_765]
compound symmetry .
The first covariance structure that converges will be used.
The treatment p -value will be used as evidence of difference between active drug and placebo, 
while the comparison o f least-squares (LS) means versus placebo (unadjusted for mult iple 
comparisons) will provide magnitud e and significance of this difference . The primary  analysis 
model, MMRM, will be repeated using the PP populat ion.  If the conclusio n differs fro m that of 
the mITT popul ation, the data and analyses will be further investigated.  
Descript ive statistics by [CONTACT_830368]1c and HbA1c change from baseline at the 12-week 
endpo int will be presented using all observed data with no imputations and no eliminat ion of 
patients wi th protocol  violations.  The descript ive statist ics will be presented by [CONTACT_830369], mean, SD, median, minimum, and maximum.
[IP_ADDRESS]. Secondary Analyses
[IP_ADDRESS].1. Analyses on Secondary Efficacy Endpoints
In addit ion to the primary  efficacy analysis of HbA1c, the following secondary  efficacy  
outcom es will  be analyzed on the m ITTpopulat ion:
Body  weight change from  baseline to 3 months
Percentage of patients reaching the HbA1c target of 7.0%
Change from baseline o f FBG at 3 months
I8F-MC-GPGF Cli nical Protocol Page 55
LY3298176Change from baseline o f waist circumference at 3 mo nths.
The secondary  continuous efficacy measures (change fro m baseline in body  weight, wai st 
circumference, and FBG) will also be analyzed using the MMRM models described above (with 
censoring data collected after initiation of rescue intervent ion).  The MMRM model will include 
the model term s given for the previously  described primary  analysis m odel except the baseline of 
the corresponding variable replacing the baseline of HbA1c, and with the addi tion of  the HbA1c 
strata (<8.5% or ≥8.5%).Baseline BMI category  will be dropped from  the analys is models f or 
body  weight change from baseline.
The percentage of patients reaching the HbA1c target of 7.0% at [ADDRESS_1152458] ics 
will include sample size, frequency , and percentage.
[IP_ADDRESS]. Exploratory Analyses
The change from baseline of 7- point SMBG profiles will be analyzed using analysis of 
covari ance m odel (ANCOVA) wi th treatm ent, baseline strata (met formin category , BMI 
category , and HbA1C category ) as fixed effects, and the corresponding baseline as covariate .  
10.3.4. Safety An alyses
[IP_ADDRESS]. Clinical Evaluation of Safety
The safet y popul ation will be used for safet y analyses.  
Safety measures will include vital signs, body  weight, TEAEs (including SAEs and AE SIs), and 
laboratory  measures (including anti -LY3298176 ant ibodies).  Summary statistics will be 
presented by [CONTACT_381087] y measures.
The summary statistics for continuous variables will be sample size, mean, SD, median, 
minimum, and maximum.
The summary statistics for categorical variables will be sample size, frequency, and percentage.
Exposure to each therapy  during the treatm ent period of the study  will be calculated for each 
patient and summarized by [CONTACT_1570].
In addit ion, percent of patients requiring rescue therapy will be summari zed.
Addit ional analysis, suc h as concentration –safet y lab plots, may be performed if warranted upon 
review of the data.
I8F-MC-GPGF Cli nical Protocol Page 56
LY329817610.3.4.2. Adverse Events
Adverse event s will be listed by [CONTACT_4676], actual term, preferred term, severit y, and rel ationship to 
the treatment.  Adverse event swill be summarize d as TEAEs (defined as events that are newly  
reported after randomizat ion or reported to worsen in severit y from baseline).  The incidence of 
patients wi th at least [ADDRESS_1152459] 1 TEAE assessed as possibly related to the 
investigat ional drug will be summarized by  [CONTACT_1570], in addit ion to the incidence o f these 
possibly  related TEAEs by  [CONTACT_11702] .  In additi on, a summary  of TEAEs by  [CONTACT_221070].
Reported thyroid and adj udicated CVand pancreatic -related AEs will be listed by  [CONTACT_4676], and if 
there are a su fficient number of cases ,they may be summarized by [CONTACT_1570].
All SAEs will be listed by  [CONTACT_4676].  If a sufficient number of SAEs are reported, incidence 
summaries similar to incidence of TEAEs will be included.
Discontinuati ons due to TEAEs will be listed by  [CONTACT_221071].
[IP_ADDRESS]. Vital Signs
All vital signs will be listed using all randomized patients.
Descript ive statistics for the actual measurements and changes from baseline for systolic and 
diastolic BPand PRwill be presen ted by  [CONTACT_266474] t.  Corresponding figures may be 
presented.
Vital signs will  be analyzed using a similar MMRM -based model as for the primary analysis.
[IP_ADDRESS]. Laboratory Measures
Summary  statistics will be provided for laboratory  measures, by  [CONTACT_765].
Alisting of laboratory  measurements for individual patients will be presented by  [CONTACT_765].  An 
additional listing will be presented for all laboratory measurements that are outside the normal 
range.
Descript ive statistics for the laboratory analyses will be p resented by  [CONTACT_266476], 
including safet y off-treatm ent visi ts.
Laboratory  analyses wi th categori cal responses will be summarized by  [CONTACT_221072].
Shift tables will be evaluated at endpoint ( last ob servat ion carri ed forward [ LOCF ]); the 
maximum/minimum postbaseline observation (as applicable for a lab) will be compared to the 
baseline observat ion by [CONTACT_830370].
[IP_ADDRESS]. Evaluation of Immunogenicity
The frequency of ant ibody  formati on(including t iters) to LY3298176 will be determined.  If a
cross -reactivit y orneutralizat ion assay is performed, the frequency o f antibodies will be 
I8F-MC-GPGF Cli nical Protocol Page 57
LY3298176determined.  If there are a sufficient numbe r of patients wi th posi tive ant ibodies to LY3298176, 
the change of ant ibodies (negat ive to posit ive) will be summarized using shift tables.
The rel ationship between the presence of ant ibodies, antibody t iters, and clinical parameters ( eg, 
AEs, efficacy mea sures) m ay be assessed.  Li kewise, the rel ationship between ant ibody  titers, the 
PK parameters ,and PD response to LY3298176 may be assessed.
[IP_ADDRESS]. Adverse Events of Special Interest
Hypoglycemia, hypersensit ivity react ions, inject ion site reactions, acute pancr eatitis, major 
adverse CVevents , and s elected GI events such as nausea, vomit ing, and diarrhea, are defined as 
AESIs.
Descript ive statistics for the AESIs will be presented by [CONTACT_6982].  Continuous 
responses will be summarized using sample size, mean, SD, median, minimum, and maximum, 
whereas categori cal responses will  be summarized using frequencies and percentages.
Summaries and analyses for incidence, time to onset, duration, and severit y of GI events ( nausea, 
vomiting, and diarrhea )will be provi ded for each treatment group during the 12-week treatm ent 
periodand by [CONTACT_765] . The planned reports will be detailed in the statist ical analysis plan.
Addit ional analyses will be performedif necessary.
[IP_ADDRESS]. Hypoglycemic Epi[INVESTIGATOR_221024]:  docum ented symptom atic hypoglycemia, 
asymptomat ic hypoglycemia, probable symptomatic hyp oglycemia,  nocturnal hypoglycemia,
and severe hypoglycemia.  Total or overall hypoglycemia is defined as any event meet ing the 
criteria for docum ented symptom atic hypoglycemia, asymptomatic hypoglycemia, or probable 
symptom atic hypoglycemia.
The total hyp oglycemia m onthly  rate per pati ent will  be summarized where 1 month is defined as 
a 30-day period.  Thi s will be calculated by  [CONTACT_221074] 30 days.  Thi s rate will also be 
calculated per pati ent for nocturnal hypoglycemia epi[INVESTIGATOR_1841], and summarized by  [INVESTIGATOR_24258].
The incidence and rate of total hypoglycemic epi[INVESTIGATOR_221025] (incidence between visit s) an d overall.  Nocturnal hypoglycemia 
epi[INVESTIGATOR_221026].  The incidence of hypoglycemic 
epi[INVESTIGATOR_51953] a time period on treatment is defined as patients with at least 1 hypoglycemic 
epi[INVESTIGATOR_830355].  
Listings of hypoglycemic epi[INVESTIGATOR_221028].  If a sufficient number of severe hypoglycemic epi[INVESTIGATOR_266443], then 
incidence summaries similar to incidence o f hypoglycemi c epi[INVESTIGATOR_221029].
10.3.5. Pharmacokinetic/Pharmacodynamic Analyses
LY3298176 trough PK sam ples collected over the course of thi s study  will be used to assess that 
exposures in the study  are consistent with known LY3298176 PK. 
I8F-MC-GPGF Cli nical Protocol Page 58
LY3298176Addit ionally , PK/PD data from  this study  may be used as a validat ion dataset to enable 
evaluat ion of PK/PD models built based on data from the core Phase [ADDRESS_1152460] of 
immunogenicit y titers on LY3298176 PK or any  relevant PD parameters mayalso be examined.
10.3.6. Other Analyses
[IP_ADDRESS]. Subgroup Analyses
Subgroup analyses of important factors, including age, race, ethnicit y, gender, durati on of  
diabetes, baseline HbA1c (<8.5% , 8.5%), met formin use (Yes/No) at baseline, BMI, and other 
factors to be specified in the SAP are planned for the key  outcomes of HbA1c.
These will be c onducted using the ANCOVA model with strata, treatment, factor, 
treatm ent-by-factor interaction as fixed effects, and baseline as covariate.
Other exploratory  subgroup analyses may  be perform ed as deemed appropriate.
[IP_ADDRESS]. Interim Analyses
No interim analyses are pl anned for this study .  If an unplanned interim analysis is deemed 
necessary , the appropri ate Lilly medical director, or designee, will be consulted to determine 
whether it is necessary to amend the protocol.
I8F-MC-GPGF Cli nical Protocol Page 59
LY329817611. References
American Diabetes Associat ion, Workgroup on Hypoglycemia .Defining and reporting 
hypoglycemia in diabetes: a report from the American Diabetes Association Workgroup on 
Hypoglycemia. Diabetes Care . 2005;28(5):1245–1249.
Baggio LL, Drucker DJ. Bi ology of incretins: GLP -1 and GIP. Gastroen terology . 
2007;132(6):2131 –2157.
Banks PA, Freeman ML ;Practi ce Parameters Com mittee of the American Co llege of 
Gastroenterology . Practi ce gui delines in acute pancreatit is. Am J Gastroenterol . 
2006;101(10):2379 –2400.
Dungan KM, Povedano ST, Forst T, Gonzal ez JG, At isso C, Sealls W, Fahrbach JL. Once -
weekly dulaglut ide versus once -daily liraglut ide in metformin -treated pati ents wi th type 2 
diabetes (AWARD -6): a randomised, open -label, phase 3, non -inferiorit y trial. 
Lancet . 
2014;384(9951):1349–1357.
Giorgino F, Benroubi M, Sun JH, Zimmermann AG, Pechtner V. Efficacy and safety o f once -
weekly dulaglut ide versus insulin glargine in pat ients with type2 diabetes on m etformin and 
glimepi[INVESTIGATOR_14956] (AWARD -2). Diabetes Care . 2015;38(12):2241 –2249.
Herbst R, Bolton W, Sha riff A, Green JB. Cardi ovascular Outcom e Tri al Update in Diabetes: 
New Evidence, Remaining Quest ions. Current Diabetes Reports. 2017; 17:67.
Hicks KA, Tcheng JE, Bozkurt B, Chait man BR, Cutlip DE, Farb A, Fonarow GC, Jacobs JP, 
Jaff MR, Licht man JH, Limach er MC, Mahaffey  KW, Mehran R, Ni ssen SE, Smit h EE, 
Targum  SL;American College of Cardio logy;Ameri can Heart Associat ion. 2014 ACC/AHA 
key data el ements and definit ionsfor cardiovascular endpoint events in clinical trial s: a report
of the American College of Cardi ology/American Heart Associ ation Task Force on Clinical 
Data Standards ( writing committee to develop cardio vascular endpo ints data standards ). 
Circulation. 2015;132(4):302
–361.
Jendle J, Grunberger G, Blevins T, Giorgino F, Hietpas RT, Botros FT. Efficacy and safet y of 
dulaglut ide in the treatment of ty pe2 diabetes: a com prehensive review of the dulaglut ide 
clinical data focusing on the AWARD phase 3 clinical trial program. Diabetes Metab Res Rev . 
2016;32(8):776 –790.
Koizumi M, Takada T, Kawarada Y, Hi rata K, Mayumi T, Yoshida M, Sekimoto M, Hirota M, 
Kimura Y, [COMPANY_005] K, Isaji S, Otsuki M, Matsuno S ;JPN. JPN guidelines for the management 
of acute pancreatit is: diagnostic criteria for acute pancreat itis. J Hepatobiliary Pancreat Surg . 
2006;13(1):25 –32.
Nauck M, Frid A, Hermansen K, Shah NS, Tankova T, Mitha IH, Zdravkovic M, During M, 
Matthews DR ;LEAD -2 Study  Group. Efficacy and safet y comparison of liraglut ide, 
glimepi[INVESTIGATOR_14956], and placebo, all in combinat ion with metformin, in ty pe2 diabetes: the LE AD 
(liraglut ide effect and act ion in diabetes) -2 study . Diabetes Care . 2009;32(1):84 –90.
Nauck MA, Petrie JR, Sest i G, Mannucci E, Courreges JP, Lindegaard ML, Jensen CB, Atkin 
SL;Study  1821 Investi gators. A Phase 2, randomized, dose -finding study  of the novel once -
weekly human GLP -1 analog, semaglut ide, compared with placebo and open -label liraglut ide 
in patients with t ype2 diabetes. Diabetes Care . 2016;39(2):231 –241.
I8F-MC-GPGF Cli nical Protocol Page 60
LY3298176Thygesen K, Alpert JS, Jaffe AS, Simoons ML, Chait man BR, White HD, Joint 
ESC/ACCF/AHA/ WHF Task Force for the Universal Definit ion of Myocardial Infarction, 
Katus HA, Lindahl B, Morrow DA, Clemmensen PM, Johanson P, Hod H, Underwood R, Bax 
JJ, Bonow RO, Pi[INVESTIGATOR_1946] F, Gibbons RJ, Fox KA, Atar D, Newby  [CONTACT_170284], Galvani M, Hamm CW, 
Uretsky  BF, Steg PG, W ijns W, Bassand JP, Menasche P, Ravkilde J, Ohman EM, Ant man 
EM, Wallent in LC, Armstrong PW, Simoons ML, Januzzi JL, Nieminen MS, Gheorghiade M, 
Filippatos G, Luepker RV, Fortmann SP, Rosamond WD, Levy D, Wood D, Smith SC, Hu D, 
Lopez -Sendon JL, Robertson RM, Weaver D, Tendera M, Bove AA, Parkho menko AN, 
Vasilieva EJ, Mendis S. Third universal definit ion of myocardial infarct ion. Circulation. 
2012;126(16):2020 –2035.
I8F-MC-GPGF Cli nical Protocol Page 61
LY329817612. Appendices
I8F-MC-GPGF Clinical Protocol Page 62
LY3298176Abbreviations and Definitions Appendix 1.
Term Definition
ADA antidrug antibodies
AE adverse event:  Any untoward medical occurrence in a patient or clinical investigation 
subject administered a pharmaceutical product that does not necessarily have a causal 
relatio nship with this treatment.  An adverse event can therefore be any unfavorable and 
unintended sign (including an abnormal laboratory finding), symptom, or disease 
temporally associated with the use of a medicinal (investigational) product, whether or 
not related to the medicinal (investigational) product.
AESI adverse event of special interest
ALP alkaline phosphatase
ALT alanine aminotransferase
ANCOVA analy sis of covariance
AST aspartate aminotransferase
blinding/masking A single -blind study is one in which the investigator and/or his staff are aware of the 
treatment but the patient is not, or vice versa, or when the sponsor is aware of the 
treatment but the investigator and/his staff and the patient are not.
A double -blind study is one in which neither the patient nor any of the investigator or 
sponsor staff who are invol ved in the treatment or clinical evaluation of the subjects are 
aware of the treatment received.
BG blood glucose
BMI body mass index
BP blood pressure
CFBL change from baseline
CIOMS Council forInternational Organizations ofMedical Sciences
complaint A complaint is any written, electronic, or oral communication that alleges deficiencies 
related to the identity, quality, purity, durability, reliability, safety or effectiveness, or 
performance of a drug or drug delivery system.
CRF case report form
CRP clinical research physician: individual responsible for the medical conduct of the study.  
Responsibilities of the CRP may be performed by a physician, CRS, global safety 
physician, or other medical officer.
CRS clinical research scientist
I8F-MC-GPGF Cli nical Protocol Page [ADDRESS_1152461] computed tomography
CV cardiovascular
documented 
symptomatic 
hypoglycemiaDefined as any time a patient feels that he/she is experiencing symptoms and/or signs 
associated with hypoglycemia, and has a plasma glucose level of 3.9mmol/L 
(70mg/dL) .
DPP-4i dipeptidy l peptidase 4 inhibitor (an OAM)
ECG electrocardiogram
eCRF electronic case report form
EDTA ethylenediaminetetraacetic acid
enroll The act of assigning a patient to a treatment.  Patients who are enrolled in the trial are 
those who have been assigned to a treatment.
eGFR estimated glomerular filtration rate
enter Patients entered into a trial are those who sign the informed consent form directly or 
through their legally acceptable representatives.
ERB ethical review board
ET early termination
ET early  termination
FBG fasting blood glucose
FSH follicle -
stimulating hormone
GCP Good Clinical Practice
GI gastrointestinal
GIP glucose -dependent insulinotropic peptide
GLP-
[ADDRESS_1152462]
HbA1c hemoglobin A1c
HIV human immunodeficiency virus
IB Investigator’s Brochure
ICF informed consent form
ICH International Council for Harmonisation
I8F-MC-GPGF Cli nical Protocol Page 64
LY3298176investigational 
productA pharmaceutical form of an active ingredient or placebo being tested o r used as a 
reference in a clinical trial, including products already on the market when used or 
assembled (formulated or packaged) in a way different from the authorized form, or 
marketed products used for an unauthorized indication , or marketed products used to 
gain further information about the authorized form.
ITT intention -to-treat:  The principle that asserts that the effect of a treatment policy can be 
best assessed by [CONTACT_41445] a patien t (ie, the 
planned treatment regimen) rather than the actual treatment given.  It has the 
consequence that patients allocated to a treatment group should be followed up, 
assessed, and analyzed as members of that group irrespective of their compliance to th e 
planned course of treatment.
IWRS Interactive Web Response System
LH luteinizing hormone
LOCF last observation carried forward
LS least squares
MI myocardial infarction
mITT modified intent -to-treat
MMRM mixed model for repeated measures
OAM oral antihy pergly cemic medication
OTC over-the-counter
PD pharmacodynamic(s)
PK pharmacokinetic(s)
PP per-protocol dataset:  The set of data generated by [CONTACT_221075], according to the underlying scientific model.
PR pulse rate
QTc corrected QT interval
QW once weekly
SAE serious adverse event
SAP statistical analysis p
lan
SC subcutaneous
screen The act of determining if an individual meets minimum requirements to become part of 
a pool of potential candidates for participation in a clinical study.
I8F-MC-GPGF Cli nical Protocol Page [ADDRESS_1152463] deviation
SMBG self-monitoring of blood glucose
S[LOCATION_003]R suspected unexpected serious adverse reactions
T2DM type 2 diabetes mellitus
TE-ADA treatment -emergent antidrug antibodies
TEAE treatment -emergent adverse event:  An untoward medical occurrence that emerges 
during a defined treatment period, having been absent pretreatment, or worsens relative 
to the pretreatment state, which and does not necessarily have to have a causal 
relatio nship with this treatment.
TIA transient ischemic attack
ULN upper limit of normal (reference range)
I8F-MC-GPGF Clinical Protocol Page 66
LY3298176Clinical Laboratory  Tests Appendix 2.
Clinical Laboratory Testsa
Hematology: Clinical Chemistry:
Hemoglobin Serum Concentrations of:
Hematocrit Sodium
Erythrocy te count (RBC) Potassium
Mean cell volume Total bilirubin
Mean cell hemoglobin concentration Direct bilirubin
Leukocytes (WBC) ALP
Neutrophils, segmented ALT
Lymphocy tes AST
Monocytes BUN
Eosinophils Creatinine
Basophils Uric acid
Platelets Calcium
Total Protein
Hemoglobin A1c Lipase
Amy lase
Urinalysis: eGFR b
pH Glucose, fasting or random
Protein Albumin
Glucose Calcitonin
Blood Hormones (females):
Urine leukocyte esterase Pregnancy Test, serum and/or urine c
Serum FSH d
Lipid Panel (Fasting)
Total Cholesterol
Triglycerides Serology e
HDL -C Hepatitis B Surface Ag
LDL -C (calculated) Hepatitis C Ab
HIV Ab
Immunogenicity :
Anti-LY3298176 antibodies GIP and GLP -1 (total and active)
Anti-LY3298176 antibody neutralization assay
Optional urine drug screen (local, at the 
discretion of the investigator)Nonpharmacogenetic Stored Samples
EDTA plasma
Serum
Abbreviations:   Ab = antidrug antibody; Ag = antigen; ALP = a lkaline phosphatase ; ALT = a lanine 
aminotransferase; AST = a spartate aminotransferase; BUN = b lood urea nitrogen; EDTA = 
ethylenediaminetetraacetic acid; eGFR = estimated glomerular filtration rate; FSH = follicle -stimulating 
hormone; GIP = glucose -dependent insulinotropic peptide; GLP-1 = glucago n-like peptide -1; HIV = human 
immunodeficiency virus; LH = luteinizing hormone; RBC =red blood cells; UACR = urine 
albumin -to-creatinine ratio; WBC = white blood cells.
aAll tests will be performed by a Lilly -designated central laboratory, unless otherwise noted .
I8F-MC-GPGF Cli nical Protocol Page [ADDRESS_1152464] will be performed by [CONTACT_82408] 1 for women of child -bearing potential; 
urine pregnancy tests may be performed at the i nvestigator’s discretion during the study.  A local laboratory may 
be used for urine pregnancy tests.   Of note, women of child -bearing potential must have a local (urine) pregnancy 
test prio r to the first dose of study drug (Visit 3) to confirm lack of pre gnancy.
dPerformed at screening by [CONTACT_221076]. Women who meet the criteria for 
postmenopausal status in Section 6.1by [CONTACT_117310]/or cessation of menses do not need to have postmenopausal 
status confirmed with hormone tests . 
ePerformed at screening only.
I8F-MC-GPGF Clinical Protocol Page [ADDRESS_1152465] igator is responsible for ensuring:
that the patient understands the potential risks and benefits of part icipating in the 
study
thatinformed consent is given by [CONTACT_57996].  This 
includes obtaining the appropriate signatures and dates on the ICF prior to the 
perform ance of any protocol  procedures and prior to the administration of 
investigat ional product.
answering any quest ions the pati ent m ay have throughout the study  and sharing in 
a timely manner any  new informat ion that m ay be rel evant to the pati ent’s 
willingness to continue his /her parti cipati on in the tri al.
Appendix 3.1.2. Ethical Review
The invest igator or an appropriate local representative must give assurance that the ERB was 
properly const ituted and convened as required by  [CONTACT_221077] (ICH) 
guidelines and other applicable laws and regulations.
Docum entati on of ERB approval  of the protocol and the ICF must be provided to Lilly  before the 
study  may begin at the investi gative si te(s).  Lilly  or its representatives must approve the ICF, 
including any  changes made by [CONTACT_41429], before it is used at the invest igative site(s).  All ICFs 
must be compliant with the ICH guideline on GCP.
The study  site’s ERB(s) shoul d be provided wi th the f ollowing:
the current IB, and updates during the course of the study
ICF
relevant curri cula vi tae.
Appendix 3.1.3. Regulatory Conside rations
This study  will be conducted in accordance wit h:
1.consensus ethics principles derived fro m internat ional ethics guidelines, including 
the Decl aration of Helsinki and Council forInternational Organizati onsof
Medical Sciences (CIOMS ) Internati onal E thical Gui delines
2.applicable ICH GCP Guidelines
3.applicable laws and regulations .
Some of the obligat ions of the sponsor will be assigned to a third party .
I8F-MC-GPGF Cli nical Protocol Page 70
LY3298176Appendix 3.1.4. Investigator Information
Physicians with a specialt y in diabetes/endocrinology, inter nal medicine, or family medicine will 
participate as invest igators in this clinical trial.
Appendix 3.1.5. Protocol Signatures
The sponsor’s responsible medical o fficer will approve the protocol, confirming that, to the best 
of his/her knowl edge, the proto col accurately describes the planned design and conduct of the 
study .
After reading the protocol, each principal invest igator will sign the protocol signature [CONTACT_25327] a copy  of the signed page to a Lilly representative.
Appendix 3.1.6. Final Report S ignature
The CSR coordinat ing invest igator will sign the final CSR for this study, indicating agreement 
that, to the best of his /her knowl edge, the report accurately  describes the conduct and results of 
the study .
The invest igator with the most enrolled patients will serve as the CSR coordinat ing investigator.  
If this invest igator is unable to fulfill this funct ion, another invest igator will be chosen by [CONTACT_229511].
The sponsor’s responsible medical o fficer and st atisti cian will approve the final CSR for this 
study , confirming that, to the best of his /her knowledge, the report accurately describes the 
conduct and results of the study .
Appendix 3.2. Data Quality Assurance
To ensure accurate, complete, and reliable d ata, Lilly  or its representatives will do the fo llowing:
provi de instructi onal materi al to the study  sites, as appropriate
sponsor start -up training to instruct the invest igators and study  coordinators.  This 
training will give instruction son the protocol, the complet ion of the CRFs, and 
study  procedures.
make periodic visit s to the study  site
be available for consultation and stay  in contact [CONTACT_129237], tel ephone, and/or fax
review and evaluate CRF data and use s tandard computer edits to detect errors in 
data collect ion
conduct a qualit y review of the database .
In addit ion, Lilly or its representatives will periodically check a sample of the patient data 
recorded against source documents at the study  site.  The st udy may be audited by  [CONTACT_47551] i ts 
representatives, and/or regulatory  agencies at any  time.  Invest igators will be given notice before 
an audit occurs.
I8F-MC-GPGF Cli nical Protocol Page [ADDRESS_1152466] data or ECG data, will be stored electronically in the central vendor’s 
database system.  Data will subsequent ly be transferred from the central vendor to the Lilly data 
warehouse.
Any data for which paper documentation provided by [CONTACT_92365] i dentified and documented by  [CONTACT_92366]’s study  file.  Paper 
docum entati on provi ded by  [CONTACT_81146], for example, a paper diary  to collect 
patient-reported outcome (PRO) measu res (eg, a rating scale), a daily dosing schedule, or an 
event di ary.
Data from co mplaint forms submitted to Lilly will be encoded and stored in the global product 
complaint m anagement sy stem .
Appendix 3.3. Study and Site Closure
Appendix 3.3.1. Discontinu ation of Study Sites
Study  site parti cipat ion may be discont inued if Lilly , the invest igator, or the ERB of the study  
sitejudges it necessary for medical, safety , regul atory , or other reasons consistent with 
applicable laws, regulat ions, and GCP.
Appendix 3.3.2. Discontinuation of the Study
The study  will be di scontinued if Lilly judges it necessary for medical, safet y, regul atory , or 
other reasons consistent with applicable laws, regulat ions, and GCP.
I8F-MC-GPGF Clinical Protocol Page [ADDRESS_1152467] Anti-F actin antibody a
GGT Anti-smooth muscle antibody a
CPK
Abbreviations:  ALP = a lkaline phosphatase ;ALT = alanine aminotransferase; AST = aspi[INVESTIGATOR_82355]; 
CPK = creatinine phosphokinase; GGT = gamma -glutamyl transferase; Ig = immunoglobulin; INR = 
international normalized ratio; RBC = red blood cells; WBC = white blood cells.
aAssay ed by [CONTACT_11007] -designated or local laboratory.
bReflex/confirmation dependent on regulatory requirements and/or testing availabili ty.
I8F-MC-GPGF Clinical Protocol Page 73
LY3298176Criteria for Diagnosing Ty pe 2 Diabetes Appendix 5.
Mellitus (American Diabetes A ssociation 201 7)
Criteria for Diabetes Diagnosis:  4 Options
Fasting blood glucose ( FBG )≥126 m g/dL (7.0 mmo l/L)
Fasting is defined as no caloric intake for at least 8 hours .*
2-hr plasma glucose ( PG)≥200 mg/dL (11.1 mmo l/L) during oral glucose tol erance test 
(OGTT )
The test should be performed as described by [CONTACT_830371] (WHO ), 
using a glucose load containing the equivalent of 75 g anhydrous glucose disso lved in 
water .*
A1c ≥6.5% (48 mmo l/mol)
The test should be perf ormed in a laboratory using a method tha t is National 
Glycohemoglo bin Standardizat ion Program  (NGSP )-certified and standardized to the 
Diabetes Control  and Com plicati ons Tri al (DCCT )assay. *
In a pati ent with classic symptom s of hyperglycemia or hy perglycemic cri sis, a r ando m 
PG ≥200 mg/dL (11.1 mmo l/L).
*In the absence o f unequivocal hyperglycemia, results should be confirmed by [CONTACT_15013].
Reference :
American Diabetes Associat ion. Classificat ion and diagnosis of diabetes . Diabetes Care .
2017;40(Suppl. 1):S11 –S24.
I8F-MC-GPG FClinical Protocol Page [ADDRESS_1152468] ive form of contracepti on, which can be any  of the 
following:
diaphragm  with spermicide
cervical sponge
cervical cap with spermicide
combined oral contraceptive pi[INVESTIGATOR_81061] -pi[INVESTIGATOR_4382]
NuvaRing
implantable contraceptives
injectable contraceptives (such as Depo- Provera )
intrauterine device (such as Mirena and ParaGard )
true abst inence, when in line wit h the preferred and usual lifestyle o f the pati ent.
Men who have had a vasectomy wit h appropri ate postvasectomy documentation of the absence 
of sperm  in the ejaculate are not required to use contraception.  In ad dition, Inclusi on 
Criterion 3b (Secti on 6.1) provides a specific definit ion of women not of child -bearing potential; 
these subjects will not be req uired to use contraception.  Male patients with a female partner 
meet ing the definit ion of a wom an not of child -bearing potential will not be required to use 
contraception.
Women of Child Bearing Potential
Women of child -bearing potenti al will be requi red to use contraception, which can be any o f the 
following:
Abstinence: I f this is co mplete abst inence, as their preferred and usual lifest yle or in a same 
sex rel ationship (as part of their preferred and usual lifest yle) must agree to either remain 
abstinent or stay  in a same sex relat ionship wi thout sexual relationships wit h males.
Birth Control :  Use of 1highly  effective m ethod ( <1% failure rate) of contraception, or a 
combinat ion of 2effect ive methods of contraception for the ent irety of the study :
oEither 1highly effect ive method of contraception (such as combinat ion oral  
contraceptives, implanted contraceptives ,or intrauterine device) 
oA combinat ion of 2effective methods of contraception (such as male or female condo ms 
with spermicide, di aphragms with spermicide , or cervical sponges) will be used. The 
subject may choose to use a double barrier method of contracepti on.Barrier protection 
methods wi thout concomitant use of a spermicide are not a reliable or acceptable method. 
Thus, each barrier m ethod m ust include use of a spermicide. 
I8F-MC-GPG FClinical Protocol Page 75
LY3298176Itshould be noted that the use of male and female condoms as a double barrier method is not
considered acceptable due to the high failure rate when these methods are combined.
I8F-MC-GPG FClinical Protocol Page 76
LY3298176World Health Organization Standardiz ed Appendix 7.
Protocols for the Measurement of Height and Weight
The fo llowing informat ion has been adapted fro m standardized physical measurement protocols 
for the Worl d Heal th Organizati on’s STEPwi se approach to Surveillance (STEPS) (WHO 20 17).
Measuring Height
Step 1.  Ask the patient to remove their footwear and any headgear (light headgear worn for 
religious reasons can remain, but this should be worn by [CONTACT_221082]).
Step [ADDRESS_1152469] (stadiometer) or 
against a wall wit h their feet together and their knees straight with their heels against the back 
board or the stadio meter or the wall.
Step 3 .  Ask the patient to look straight ahead without tilt ing their h ead up.
Step 4 .  Ask the patient to breathe in and stand tall. If using a stadio meter or fixed measuring 
device, move the device’s measurement arm gent ly down onto the top of the patient’s head. 
Record the pati ent’s height in cent imeters (cm).
Measuring Weight
Body  weight m easurements shoul d be done in a consistent manner using a calibrated scale 
(digital). All weights for a given pat ient shoul d be measured using the same scale, whenever 
possible, after the patient has empt ied their bladder. Patients sh ould wear a light hospi[INVESTIGATOR_830356].
Step 1 .Ask the patient to remove their outer cl othing and footwear (underwear may remain on), 
and change into a light hospi[INVESTIGATOR_105463] .
Step 2 .Make sure the scale is placed on a firm, flat, e ven surface (not on carpet or on a slopi[INVESTIGATOR_221032] a rough uneven surface).
Step [ADDRESS_1152470] t heir weight in 
kilograms (kg).
Reference:
[WHO] Worl d Heal th Organizat ion. STEPwi se approach to Surveillance (STEPS). Updated 
2017.Available at: http://www.who.int/chp/steps/Part3_Section3.pdf . Accessed 31 July  2017 .
Leo Document ID = 784a9ec8-125f-47cb-8aea-83d160dd2ea3
Approver: 
Approval Date & Time: 01-Aug-2017 18:36:27 GMT
Signature [CONTACT_32869]: Approved
Approver: 
Approval Date & Time: 02-Aug-2017 18:23:57 GMT
Signature [CONTACT_32869]: Approved
[COMPANY_003]
[COMPANY_003]